Effects of chemotherapy-induced ovarian failure on bone and lipid metabolism in premenopausal breast cancer patients : Impact of adjuvant clodronate and tamoxifen by Vehmanen, Leena
 EFFECTS OF CHEMOTHERAPY-
INDUCED OVARIAN FAILURE ON 
BONE AND LIPID METABOLISM IN 
PREMENOPAUSAL BREAST CANCER 
PATIENTS 
 
Impact of adjuvant clodronate and 
tamoxifen 
 
 
 
 
 
 
Leena Vehmanen 
 
 
 
Department of Oncology 
 
University of Helsinki 
 
Finland 
 
 
Academic Dissertation 
 
 
To be publicly discussed, with the permission of the Medical Faculty of the 
University of Helsinki, in the Auditorium of the Department of Oncology, Helsinki 
University Hospital, Haartmaninkatu 4, on June 17th, 2005, at 12 o’clock noon. 
 
Helsinki 2005 
 
ISBN 952-91-8799-8 (nid.)
ISBN 952-10-2498-4 (PDF)
Helsinki 2005
Yliopistopaino
 CONTENTS 
 
1. LIST OF ORIGINAL PUBLICATIONS...............................................................1 
2. ABBREVIATIONS..................................................................................................2 
3. ABSTRACT..............................................................................................................4 
4. INTRODUCTION....................................................................................................6 
REVIEW OF THE LITERATURE ...........................................................................8 
5. ADJUVANT TREATMENT OF BREAST CANCER .........................................8 
5.1. Adjuvant chemotherapy of breast cancer............................................................9 
5.1.1 General aspects .............................................................................................9 
5.1.2 Different adjuvant chemotherapy regimens................................................10 
5.2. Adjuvant endocrine therapy of breast cancer....................................................15 
5.2.1 General aspects ...........................................................................................15 
5.2.2 Different endocrine therapy regimens ........................................................16 
5.2.2.1 Selective estrogen receptor modulators ...............................................16 
5.2.2.2 Aromatase inhibitors............................................................................19 
5.2.2.3 Ovarian ablation...................................................................................21 
5.2.2.4 Side effects of different endocrine therapy regimens ..........................24 
6. LONG-TERM EFFECTS OF ADJUVANT TREATMENTS ON BONE 
METABOLISM..........................................................................................................26 
6.1 Bone structure and metabolism..........................................................................26 
6.2 Methods of examining bone metabolism...........................................................27 
6.2.1 Bone mineral density (BMD)......................................................................27 
6.2.2 Biochemical markers of bone turnover.......................................................28 
6.2.2.1 PINP and ICTP as markers of bone turnover.......................................29 
6.3 Chemotherapy and bone metabolism.................................................................30 
6.4 Endocrine therapy and bone metabolism...........................................................31 
6.5 Osteoporosis.......................................................................................................34 
6.5.1 Treatment of osteoporosis – general ...........................................................35 
6.5.2 Treatment of osteoporosis in women with a history of breast cancer.........37 
7. BISPHOSPHONATE TREATMENT IN BREAST CANCER .........................39 
7.1 Bone metastasis – general ..................................................................................39 
7.2 Mechanism of action of the bisphosphonates ....................................................40 
7.3 Bisphosphonate treatment in metastatic breast cancer.......................................42 
7.4 Adjuvant bisphosphonate treatment in breast cancer.........................................43 
7.4.1 Effect on survival........................................................................................43 
7.4.2 Effect on bone mineral density ...................................................................46 
 
 8. LONG-TERM EFFECTS OF ADJUVANT TREATMENTS ON LIPID 
METABOLISM..........................................................................................................47 
8.1 Lipid metabolism and atherosclerosis................................................................47 
8.2 Estrogen and lipid metabolism...........................................................................48 
8.3 Adjuvant chemotherapy and serum lipids..........................................................49 
8.4 Adjuvant endocrine therapy and serum lipids ...................................................50 
9. AIMS OF THE PRESENT STUDY .....................................................................53 
10. PATIENTS AND METHODS (I-IV) .................................................................54 
10.1 Patients .............................................................................................................54 
10.2 Methods............................................................................................................55 
10.2.1 Clinical investigation and menopausal status ...........................................55 
10.2.2 Dual energy X-ray absorptiometry (DXA) ...............................................56 
10.2.3 Radioimmunoassays for bone markers PINP and ICTP...........................56 
10.2.4 Assays of serum lipid levels .....................................................................56 
10.2.5 Statistical methods ....................................................................................57 
11. RESULTS .............................................................................................................59 
11.1 Chemotherapy, clodronate and tamoxifen treatment: Effects on bone mineral 
density (I, II, III) ......................................................................................................59 
11.1.1 Effect of chemotherapy on bone mineral density (I, II, III)......................59 
11.1.2 Effect of clodronate on bone mineral density (I, II) .................................60 
11.1.2.1 Effect of peroral long-term clodronate on bone mineral density (I) ..60 
11.1.2.2 Effect of intravenous short-term clodronate on bone mineral density 
(II) ....................................................................................................................61 
11.1.2.3 Effect of short-term intravenous clodronate on bone markers PINP 
and ICTP (II)....................................................................................................62 
11.1.3 Effect of tamoxifen on bone mineral density (III) ....................................63 
11.2 Chemotherapy and tamoxifen treatment: Effects on serum lipids (IV)...........64 
11.2.1 Effect of chemotherapy on serum lipids (IV) ...........................................64 
11.2.2 Effect of tamoxifen on serum lipids (IV)..................................................66 
12. DISCUSSION .......................................................................................................69 
12.1 Adjuvant chemotherapy and bone mineral density..........................................69 
12.2 Effect of clodronate on bone loss induced by adjuvant chemotherapy ...........70 
12.3 Effect of intravenous clodronate on bone markers PINP and ICTP ................72 
12.4 Effect of tamoxifen after adjuvant chemotherapy on bone mineral density....73 
12.5 Adjuvant chemotherapy and serum lipids........................................................75 
12.6 Effect of tamoxifen after adjuvant chemotherapy on serum lipids..................76 
13. CONCLUSIONS ..................................................................................................78 
14. ACKNOWLEDGEMENTS ................................................................................79 
15. REFERENCES.....................................................................................................81 
 
 1. LIST OF ORIGINAL PUBLICATIONS 
 
 
This thesis is based on the following original publications, which are referred in the 
text by their Roman numerals (I-IV): 
 
I. Vehmanen L, Saarto T, Elomaa I, Mäkelä P, Välimäki M, 
Blomqvist C. Long-term impact of chemotherapy-induced ovarian 
failure on bone mineral density (BMD) in premenopausal breast 
cancer patients. The effect of adjuvant clodronate treatment. Eur J 
Cancer 37:2373-8, 2001  
 
II. Vehmanen L, Saarto T, Risteli J, Risteli L, Blomqvist C, Elomaa I. 
Short-term intermittent intravenous clodronate in the prevention of 
bone loss related to chemotherapy-induced ovarian failure. Breast 
Cancer Res Treat 87:181-8, 2004 
 
III. Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen 
treatment after adjuvant chemotherapy has opposite effects on bone 
mineral density in premenopausal patients depending on menstrual 
status: Tamoxifen causes bone loss in patients who continue to 
menstruate but reduces bone loss in those with amenorrhea. 
(submitted) 
 
IV. Vehmanen L, Saarto T, Blomqvist C, Taskinen MR, Elomaa I. 
Tamoxifen treatment reverses the adverse effects of chemotherapy-
induced ovarian failure on serum lipids. Br J Cancer 91:476-81, 
2004 
 
 
 
1
 
 2. ABBREVIATIONS 
 
A   doxorubicin (Adriamycin®) 
AC   doxorubicin –cyclophosphamide 
AF1  activation domain 1 
AF2  activation domain 2 
AFOS  alkaline phosphatase 
ATP   adenosine triphosphate 
AVCF   doxorubicin -vincristine-cyclophospamide-5-fluorouracil 
BMD   bone mineral density 
CAF, FAC  cyclophosphamide, doxorubicin, 5-fluorouracil 
CEF, FEC  cyclophosphamide, epirubicin, 5-fluorouracil 
CHD   coronary heart disease 
CI  confidence interval 
CMF   cyclophosphamide, methotrexate, 5-fluorouracil 
CMFp   cyclophosphamide, methotrexate, 5-fluorouracil, prednisone 
CRP   C-reactive protein 
CTX   cross-linked carboxytelopeptide of type I collagen 
DCIS   ductal carcinoma in situ 
DFS   disease-free survival 
DNA  deoxyribonucleic acid 
DXA   dual X-ray absorptiometry 
ER   estrogen receptor 
FSH  follicle stimulating hormone 
G1  first growth phase of the replicative cycle 
HDL   high-density lipoprotein 
HER-2-neu  human epidermal growth factor receptor 2 
HRT   hormone replacement therapy 
ICTP   cross-linked carboxy-terminal telopeptide of type I collagen 
i.v.   intravenous 
LDL   low-density lipoprotein 
LH  luteinizing hormone 
Lp(a)  lipoprotein a 
MPP   matrix metalloproteinase 
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 NTX   cross-linked aminotelopeptide of type I collagen 
OS   overall survival 
PINP   aminoterminal propeptide of type I procollagen 
PR   progesterone receptor 
PST   primary/preoperative systemic therapy 
PTH   parathyroid hormone 
PTHrP  parathyroid hormone- related peptide 
RR   response rate 
SERM  selective estrogen receptor modulator 
SD  standard deviation 
T   docetaxel (Taxotere®) 
TAC   docetaxel, doxorubicin, cyclophosphamide 
TNM   primary tumor (T), regional lymph nodes (N), metastasis (M) 
v.   versus 
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 3. ABSTRACT 
 
Adjuvant cytotoxic chemotherapy causes ovarian failure and amenorrhea in most 
premenopausal women with early breast cancer. This early menopause has profound 
effects on bone and lipid metabolism. The impact of clodronate and tamoxifen 
treatment on bone mineral density (BMD) and serum lipids in premenopausal breast 
cancer patients treated with adjuvant chemotherapy was studied here.  
 
Two separate populations of premenopausal patients with early breast cancer were 
studied. The first population comprised 148 patients treated with adjuvant 
chemotherapy and randomized to oral clodronate for three years or controls. The 
second population included 159 patients treated with adjuvant chemotherapy. After 
the chemotherapy, adjuvant five-year tamoxifen was started in hormone receptor-
positive patients. In addition, the first 48 patients were randomly allocated to receive 
intermittent intravenous clodronate treatment or no further therapy. 
 
We examined the long-term effects of adjuvant peroral clodronate treatment as well as 
the effect of short-term intravenous adjuvant clodronate treatment in the prevention of 
bone loss related to chemotherapy-induced premature menopause. The impact of 
adjuvant tamoxifen treatment on BMD after adjuvant chemotherapy was also studied. 
In addition, we examined whether tamoxifen treatment could reverse the adverse 
effects of chemotherapy on serum lipid levels. 
 
Adjuvant chemotherapy caused ovarian dysfunction and amenorrhea in the majority 
of the patients. Marked bone loss occured in women who developed chemotherapy-
induced ovarian failure and early menopause, while those who continued to 
menstruate despite the chemotherapy preserved their baseline BMD levels. Three-year 
oral clodronate treatment significantly reduced bone loss associated with ovarian 
failure. Four-month intermittent intravenous clodronate treatment, on the other hand, 
did not prevent the rapid bone loss associated with chemotherapy-induced ovarian 
failure.  
 
Tamoxifen treatment after adjuvant chemotherapy had opposite effects on BMD 
depending on menstrual status. Tamoxifen caused bone loss in patients who continued 
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 to menstruate after adjuvant chemotherapy. Conversely, tamoxifen decreased bone 
loss in those women who developed chemotherapy-induced amenorrhea. 
 
Changes in total and low-density lipoprotein (LDL) cholesterol during the 
chemotherapy correlated significantly with menstrual function. Only those patients 
who developed signs of ovarian failure had marked elevations in serum total and LDL 
cholesterol, while no significant changes occurred in those who preserved regular 
menstruation. Adjuvant tamoxifen therapy reversed the adverse effects of 
chemotherapy on total and LDL cholesterol and lowered their serum levels even 
below the baseline. The serum high-density lipoprotein (HDL) cholesterol levels, 
however, remained unchanged after chemotherapy followed by tamoxifen. 
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 4. INTRODUCTION 
 
Breast cancer is the most common malignancy in women of Western countries. In 
Finland, 3774 new cases were diagnosed in 2002. Although the incidence of breast 
cancer is increasing, the mortality figures are not. Today around 85 percent of Finnish 
breast cancer patients survive five years after diagnosis (1). 
 
It is important to detect breast cancer as early as possible because the stage of the 
disease and the size of the tumor are the strongest prognostic factors for survival (2). 
Early detection programs through mass screening with mammography have been 
introduced in many countries. While some controversy exists about the survival 
benefits of mass mammography screening (3, 4), the effect of adjuvant therapies on 
breast cancer survival is well documented. Adjuvant therapy is systemic treatment 
given to kill any cancer cells that may have spread despite local therapy. 
Chemotherapy (or: cytotoxic therapy) and endocrine therapy (or: hormonal therapy) 
are used as adjuvant treatments to reduce breast cancer recurrence.  
 
Postoperative radiotherapy has long been known to reduce the local relapse rates (5) 
and in recent trials utilizing modern radiotherapy techniques survival rates have also 
been shown to improve significantly (6, 7). Adjuvant polychemotherapy reduces 
mortality by 27% in women less than 50 years old and by 11% in those aged 50-69 
years (8). Similarly, adjuvant endocrine therapy with the antiestrogen tamoxifen for 
five years reduces the risk of death by 28% (9).  
 
Breast cancer is primarily a disease of older women; only approximately 25% of 
incident cases are women younger than 50 years (10). The reproductive health effects 
of breast cancer treatments specifically affect younger women as adjuvant 
chemotherapy often causes ovarian failure and amenorrhea leading to early 
menopause (11, 12). Menopause causes changes in serum lipids that are explained by 
the deficiency of estrogens: serum total and LDL cholesterol and triglyceride levels 
increase and HDL cholesterol levels decrease (13-17). Similarly, early chemotherapy-
induced menopause leads to adverse and possibly atherogenic changes in serum lipids 
of breast cancer patients (18). Tamoxifen has an estrogen-like effect on serum lipids 
decreasing the levels of total and LDL cholesterol (19-22). Chemotherapy followed 
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 by tamoxifen is an established adjuvant treatment in hormone receptor positive breast 
cancer. So far, no studies are available on the effects of adjuvant chemoendocrine 
therapy on serum lipid levels. 
 
The chemotherapy-induced ovarian failure has adverse effects on bone metabolism as 
it causes rapid bone loss (11, 23-26). Bisphosphonates prevent bone loss in patients 
with established osteoporosis (27-32). In women with advanced breast cancer and 
clinically evident bone metastases, the use of bisphosphonates reduces the risk of 
skeletal complications (33).  Clodronate, a bisphosphonate available both as an oral 
and intravenous remedy, has been shown to reduce the rapid bone loss related to 
chemotherapy-induced amenorrhea (26). The optimal duration and route (oral or 
intravenous) of adjuvant clodronate treatment is not known. Although tamoxifen 
prevents bone loss and increases BMD in postmenopausal women (34-38), it may 
induce bone loss in young, premenopausal patients (38). The effects of tamoxifen 
treatment on BMD after a period of adjuvant chemotherapy have not been studied 
before. 
 
Today, more and more women survive breast cancer. While maximal long-term 
efficacy remains the mainstay of all adjuvant treatments, there is growing concern 
about the long-term safety and tolerability of these treatments as well. Chemotherapy-
induced early menopause leads to adverse effects in serum lipid profile and causes 
accelerated bone loss. Consequently, many breast cancer survivors may have an 
increased risk of developing cardiovascular disease and osteoporosis. This thesis 
focuses on the long-term sequelae of adjuvant treatments on lipid and bone 
metabolism in premenopausal patients with early breast cancer.  
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 REVIEW OF THE LITERATURE 
 
5. ADJUVANT TREATMENT OF BREAST CANCER 
 
In women with early breast cancer, the disease is, by definition, restricted to the breast 
and, in node-positive cases to the local lymph nodes. Although all detectable cancer 
tissue is removed surgically, undetected micrometastatic deposits of the disease may 
remain and subsequently develop into clinically evident metastatic disease. Adjuvant 
cytotoxic and endocrine therapies significantly reduce the risk of recurrence and 
improve survival in women with early-stage, primary breast cancer (39, 8, 9). 
 
Today, adjuvant therapy is recommended for most breast cancer patients with the 
possible exception of women with a minimal risk for cancer recurrence (40). The 
most relevant factor for the estimation of risk of recurrence is the nodal status (41). 
The College of American Pathologists includes the TNM (primary tumor (T), regional 
lymph nodes (N), metastasis (M)) staging information, hormone receptor status of the 
tumor, histologic grade, histologic type and mitotic figure counts as factors proven to 
be of prognostic importance and useful in clinical patient management (42). Other, to 
date less extensively studied prognostic factors, include HER-2-neu (human 
epidermal growth factor receptor), proliferation markers and lymphatic and vascular 
channel invasion (42).  Young age (< 35 years) is considered as an independent 
adverse prognostic factor (43).  
 
Adjuvant treatments are recommended in the presence of unfavorable prognostic 
factors. The selection of a suitable adjuvant therapy is based primarily on the 
assessment of endocrine-responsiveness according to the presence of estrogen (ER) 
and progesterone receptors (PR) in the primary tumor (40). Patients with endocrine-
nonresponsive disease (absence of detectable steroid hormone receptors) are treated 
with adjuvant chemotherapy alone as such patients do not benefit from endocrine 
therapy. Patients with endocrine-responsive tumors (presence of detectable steroid 
hormone receptors), on the other hand, are offered either endocrine therapy alone or a 
combination of chemotherapy and endocrine therapy.  
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 5.1. Adjuvant chemotherapy of breast cancer 
 
5.1.1 General aspects 
 
The large meta-analysis conducted by the Early Breast Cancer Trialists`s 
Collaborative Group (EBCTCG) involved about 18 000 women in 47 trials of 
polychemotherapy versus no chemotherapy. According to this meta-analysis, adjuvant 
polychemotherapy produced substantial and highly significant reductions in the risk 
of both breast cancer recurrence and death. The risk reductions were age-specific. In 
women aged less than 50 years at randomization the proportional reduction in the risk 
of recurrence was 35% and in those aged 50-69 years 20 %. Only a few women aged 
70 or over were studied. For mortality, the reductions were also significant both in 
women aged less than 50 years (27%) and in those aged 50-69 (11%). The 
proportional reductions in risk of death were similar for women with node-negative 
and node-positive disease. Applying the proportional mortality reduction observed in 
women aged under 50 years at randomisation would typically change a 10-year 
survival of 71% for those with node-negative disease to 78% (an absolute benefit of 
7%), and of 42% for those with node-positive disease to 53% (an absolute benefit of 
11%). For women aged 50-69 years, adjuvant polychemotherapy would translate into 
smaller absolute benefits, changing a 10-year survival of 67% for those with node-
negative disease to 69% (an absolute benefit of 2%) and of 46% for those with node-
positive disease to 49% (an absolute gain of 3%) (8). 
 
The adjuvant chemotherapy should be started no later than a few months after the 
breast cancer surgery.  If both systemic chemotherapy and tamoxifen are given, the 
sequential administration of tamoxifen after chemotherapy is superior to concurrent 
use of these modalities. A recent trial compared CAF (cyclophosphamide, 
doxorubicin and 5-fluorouracil) for six cycles followed by tamoxifen for five years to 
CAF administered concurrently with tamoxifen. The disease-free survival (DFS) was 
significantly better after sequential treatment as compared to concurrent treatment. 
These results are consistent with the hypothesis that tamoxifen may antagonize some 
chemotherapeutic agents and support the practice standard of starting adjuvant 
tamoxifen when chemotherapy is completed (44). 
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 The optimal duration of adjuvant chemotherapy has been studied in a few trials. Three 
cycles of FEC (5-fluorouracil, epirubicin, cyclophosphamide) has been shown to be 
inferior to six cycles (45). Four courses of AC (doxorubicin, cyclophosphamide) have 
been shown to be equivalent to six cycles of classical CMF (46). Continuing adjuvant 
CMF beyond the standard treatment of six cycles did not improve survival (47).  Four 
to six cycles of adjuvant chemotherapy is considered adequate according to 
international consensus guidelines (40, 48).  
 
The question of dose intensity remains controversial in the adjuvant chemotherapy of 
breast cancer. Lower than standard doses have been shown to result in an inferior 
outcome  (45, 49). On the other hand, intensifying and increasing the total dose of 
cyclophosphamide in AC adjuvant treatment did not demonstrate any survival benefit 
(50). Adjuvant high-dose therapy with autologous bone marrow support does not 
seem to offer survival benefit as compared to conventional treatment (51-52). 
However, increasing dose density (administration of drugs with a shortened 
intertreatment interval) may improve survival (53). 
 
Some primary breast cancers are diagnosed as locally advanced (e.g. inflammatory 
cancer or involving the skin, chest wall or clavicular nodes). Primary or preoperative 
systemic therapy (PST) refers to the first postdiagnosis systemic treatment and is 
considered the standard of care for initially nonoperable, locally advanced breast 
cancer. For operable but large breast cancer, PST provides an additional opportunity 
for breast-conserving surgery. PST offers the same survival benefits, as does 
conventional postoperative adjuvant therapy (54). 
 
5.1.2 Different adjuvant chemotherapy regimens 
 
As adjuvant therapy, combination chemotherapy regimens (polychemotherapy) are 
superior to single-agent chemotherapies (39). The classical CMF (cyclophosphamide, 
methotrexate, 5-fluorouracil) treatment was introduced by Bonadonna in the mid 
1970`s and became a standard adjuvant chemotherapy for breast cancer (55). The 
Bonadonna CMF treatment consisted of cyclophosphamide 100 mg/m² orally from 
day 1 to 14, methotrexate 40 mg/m² intravenously on days 1 and 8 and 5-fluorouracil 
600 mg/m² intravenously on days 1 and 8. The long-term results of adjuvant CMF 
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 therapy confirmed the preliminary observations of the effectiveness of the treatment 
in women with node-positive breast cancer. After nearly 30 years of follow-up, the 
patients given adjuvant CMF chemotherapy still had significantly better rates of 
relapse-free survival and overall survival (OS) than the controls (56).  
 
Anthracyclines like doxorubicin and epirubicin are among the most active drugs in 
metastatic breast cancer with response rates (RRs) of approximately 30% to 50% (57-
58). Anthracycline-combinations yield significantly more objective responses in 
patients with metastatic breast cancer than the classical CMF (59). A few randomized 
studies have demonstrated the superiority of an anthracycline-containing combination 
over CMF, also in the adjuvant setting. Levine et al compared an intensive CEF 
(cyclophosphamide, epirubicin, 5-fluorouracil) adjuvant chemotherapy regimen to 
classical CMF in 710 node-positive breast cancer patients. The five-year DFS rates for 
the CEF and CMF groups were 63% and 53%. The five-year OS rates were 77% and 
70%, respectively (60). In the study by Misset et al, 249 node-positive breast cancer 
patients were randomized to receive 12 monthly cycles of either AVCF (doxorubicin, 
vincristine, cyclophosphamide and fluorouracil) or CMF. With a median follow-up 
time of 16 years, the survival rates were significantly higher in the AVCF versus (v.) 
CMF arm: for DFS 53% v. 36% and for OS 56% v. 41%, respectively (61). Similarly, 
early results (median follow-up 32 months) of the NEAT and SCTBG BR9601 trials 
(n=2391) showed that adding epirubicin to either classical or intravenous CMF 
resulted in significant benefits for both relapse-free and overall survival as compared 
to CMF alone (62). Finally, the large meta-analysis by EBCTCG confirmed that 
anthracycline-containing combinations are more effective than the CMF regimens and 
provide an extra absolute benefit of 3% at five years in terms of OS (8).     
 
The taxanes paclitaxel and docetaxel have significant antitumor activity in patients 
with metastatic breast cancer (57, 58, 63-65). Randomized trials of single-agent 
paclitaxel have reported RRs of 21% to 54% (58, 64). RRs of 30% to 48% have been 
reported in randomized trials of single-agent docetaxel treatment in metastatic breast 
cancer (57, 63, 65). The efficacy of the taxanes has been proven also in patients with 
disease progression after an anthracycline-based chemotherapy regimen (63). The 
potential benefits of adding taxanes to anthracycline-containing regimens in the 
adjuvant setting have been studied in a few major trials. The results of the largest 
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 paclitaxel (CALGB 9433 and NSABP B-28) and docetaxel (BCIRG 001 and PACS 
01) adjuvant trials are discussed below (Table 1). All these four trials included pre- 
and postmenopausal patients with node-positive early breast cancer and the results are 
reported after an approximate follow-up of five years. 
 
Two trials have examined four courses of paclitaxel after four cycles of AC in the 
adjuvant setting, but these results are difficult to interpret because of the confounding 
by duration, receptors, and the concurrent administration of tamoxifen. In the CALGB 
9344 study, patients were randomly assigned to receive a combination of 
cyclophosphamide (C) 600 mg/m², with one of three doses of doxorubicin (A), 60, 75, 
or 90 mg/m², for four cycles followed by either no further therapy or four cycles of 
paclitaxel at 175 mg/m². Tamoxifen was given to most patients with hormone 
receptor–positive tumors. In this study, there was no evidence of a doxorubicin dose 
effect. The addition of four cycles of paclitaxel after the completion of a standard 
course of AC significantly improved both DFS and OS of the patients (66). In the 
NSABP B-28 trial, patients were randomized to be treated either with adjuvant AC 
(doxorubicin 60 mg/m², cyclophosphamide 600 mg/m²) for four cycles followed by 
four cycles of paclitaxel 225 mg/m² or with AC for four cycles alone. Tamoxifen was 
started with chemotherapy for five years for patients of 50 years of age or older and to 
those younger with hormone receptor-positive tumors. The addition of paclitaxel 
significantly improved DFS as compared to AC alone, but OS did not differ between 
the treatment groups (67). 
 
Two major trials have examined the benefits of adding docetaxel to anthracycline-
containing regimens. A BCIRG 001 trial evaluated six cycles of docetaxel, 
doxorubicin and cyclophosphamide (TAC) versus six cycles of 5-fluorouracil, 
doxorubicin and cyclophosphamide (FAC). Patients received tamoxifen if 
appropriate. Both DFS and OS were significantly better in the TAC group as 
compared to FAC (68, 69). Quite recently, results of the PACS 01 trial comparing a 
FEC 100 regimen (5-fluorouracil 500 mg/m², epirubicin 100 mg/m² and 
cyclophosphamide 500 mg/m²) for six cycles to three cycles of FEC 100 followed by 
three cycles of 100 mg/m² of docetaxel were reported. Combining docetaxel with FEC 
significantly improved both DFS and OS. However, the docetaxel-FEC combination 
did not seem to offer any extra advantage for patients younger than 50 years (70). 
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 In summary, adding taxanes to anthracycline-containing regimens seems to improve 
survival in patients with node-positive early breast cancer. The improvements 
observed by the sequential addition of paclitaxel to AC in the CALGB 9344 and 
NSABP B-28 trials could be related to a true ability of paclitaxel to kill anthracycline-
resistant cancer cells or simply to the longer duration (eight v. four cycles) of the 
treatment. Adding docetaxel to AC (TAC regimen) and combining CEF and docetaxel 
sequentially has resulted in survival benefits (69, 70). More than 20 000 additional 
women have been included in randomized clinical trials investigating the role of 
taxanes that have yet to report results and the results of earlier trials are maturing. The 
findings of the major adjuvant trials comparing anthracycline-based regimens and 
taxanes are summarized in Table 1. 
 
The HER-2-neu gene, which encodes the human epidermal growth factor protein 
HER-2-neu, is amplified or HER-2-neu protein overexpressed in 25 to 30 % of breast 
cancers, increasing the aggressiveness of the tumor (71). Trastuzumab (Herceptin®) 
is a recombinant humanised monoclonal antibody that specifically targets the HER-2-
neu protein. Trastuzumab when used in combination with chemotherapy 
(cyclophosphamide plus anthracyline or paclitaxel) is more effective than 
chemotherapy alone for the treatment of metastatic breast cancer overexpressing 
HER-2-neu. However, it seems to be associated with congestive heart failure 
particularly in combination with anthracycline based chemotherapy (72). Many trials 
that study the potential role of trastuzumab in the adjuvant therapy of breast cancer 
are underway and the first results are awaited during the next few years. 
13
 
 Table 1. Major adjuvant trials comparing anthracycline-regimens and taxanes  
Trial n Treatment Patients Follow-up DFS OS 
 
CALGB 9344 3121 ACx4 v. 
ACx4 + Px4 
Pre/post 
N+ 
5 years 65% 
70%* 
77% 
80%* 
NSABP B-28 3060 ACx4 v. 
ACx4 + Px4 
Pre/post 
N+ 
5 years 72% 
76%* 
85% 
85% 
BCIRG 001 1491 FACx6 v. 
TACx6 
Pre/post 
N+ 
4.5 years 68% 
75%* 
81% 
87%* 
PACS 01 1999 FECx6 v. 
FECx3 + Tx3 
Pre/post 
N+ 
5 years 73% 
78%* 
87% 
91%* 
A=doxorubicin, C=cyclophosphamide, DFS=disease-free survival, E=epirubicin, F=5-fluorouracil, 
n=number of patients, N+=node-positive, OS=overall survival, P=paclitaxel, pre=premenopausal, 
post=postmenopausal, T=docetaxel, *=significant difference 
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 5.2. Adjuvant endocrine therapy of breast cancer 
 
5.2.1 General aspects 
 
Many breast cancers depend on estrogens for their continued growth. The binding of 
estradiol to ER in the nucleus activates interaction of the receptor-hormone complex 
with specific regions of deoxyribonucleic acid (DNA), which ultimately triggers 
cellular growth. Depriving the tumor of this stimulus is an established method of 
treating the disease (73). Regression of advanced breast cancer because of endocrine 
therapy was first described over 100 years ago (74). 
 
More than 70% of all breast carcinomas are ER positive while PR positivity is 
detected in about 60% of cases (75). ER and PR content in the primary tumor are 
powerful markers predicting endocrine responsiveness (9). The exact threshold of ER 
and PR (with immunohistochemical staining), which should be used to distinguish 
between endocrine-responsive and endocrine-nonresponsive tumor, is unknown. Even 
a low number of cells stained positive (as low as 1% of tumor cells) identify a cohort 
of tumors having some responsiveness to endocrine therapies  (76). According to an 
adjuvant consensus meeting, 10% positive staining of cells for either receptor might 
be considered as a reasonable threshold for definite endocrine responsiveness (48). 
 
The rationale for the use of adjuvant endocrine therapy is its steady efficacy for 
patients with receptor-positive breast cancer in a multitude of randomized trials, as 
summarized by the Early Breast Cancer Trialists’ Collaborative Group (9). The 
antiestrogen tamoxifen is still the gold standard for adjuvant hormonal treatment of 
breast cancer for both pre- and postmenopausal women. Aromatase inhibitors were 
initially used in the treatment of advanced breast cancer in postmenopausal women 
for whom tamoxifen failed. Since then, aromatase inhibitors have shown superior 
efficacy over tamoxifen as first-line treatment for postmenopausal women with 
advanced breast cancer (77-79). Nowadays the efficacy and tolerability of aromatase 
inhibitors has also been demonstrated in an adjuvant setting (80-86). Ovarian ablation 
significantly improves long-term survival for young premenopausal women, at least in 
the absence of chemotherapy (87). 
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 5.2.2 Different endocrine therapy regimens 
5.2.2.1 Selective estrogen receptor modulators 
 
Tamoxifen 
 
Over the past few decades, the desire to develop compounds to counteract the actions 
of estrogen for controlling breast cancer led to the identification of antiestrogens. In 
addition to the well-demonstrated antagonist effects of these compounds in estrogen-
stimulated breast tissue, it was observed that antiestrogens displayed substantial 
agonist activities in other organs. The phenomenon of variable pharmacological 
attributes of agonist/antagonist, depending on the target tissue, suggested the name 
“selective estrogen receptor modulator” or SERM (88). 
 
Tamoxifen is the prototype of a group of nonsteroidal SERMs possessing a 
triphenylbutene core and basic side chain (89). It is an antiestrogen, which blocks ER 
at tumor level by competitively inhibiting estradiol binding. This causes the cell to be 
held at the G1 phase (the first growth phase of the replicative cycle) (90, 91). Though 
the primary action of tamoxifen is competitive antagonism of estrogen at the cellular 
receptor, it also exhibits estrogen agonist properties. The main effect of tamoxifen on 
breast tissue is antiestrogenic, whereas many of its other effects, such as those on the 
uterus, lipid metabolism, the vasculature, blood clotting mechanisms, and bone 
resorption, are considered to be estrogen-agonistic (34, 89, 92, 93).  
 
The estrogen agonist/antagonist properties of SERMs can be partly explained through 
the two activation domains AF1 and AF2 of ER that mediate the transcriptional 
control of the receptor. Tamoxifen blocks the effect of estrogen by inhibiting AF2 but 
it does not inhibit AF1. Therefore, tamoxifen has primarily antagonist activity in 
breast tissue where AF2 is dominant but more agonistic activity in other tissues such 
as uterus where AF1 is dominant. Estrogen agonist or antagonist effects are thus 
dependent on the organ-specific type and amount of ER available for ligand binding 
as well as the type of target gene promoter (90). Also the menopausal status 
modulates the effect of SERMs. Tamoxifen seems more estrogen antagonist than 
agonist in premenopausal women while the estrogen agonist properties prevail in 
postmenopausal women (90).  
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 In metastatic breast cancer, tamoxifen induces RRs up to 35% in patients with ER- or 
PR-positive disease when used as a first line treatment. Another 20% of these patients 
have stable disease lasting for approximately six months (94). A large meta-analysis 
by EBCTCG studied the effects of adjuvant tamoxifen treatment in 18 000 women 
with estrogen-receptor (ER) positive primary tumors and nearly 12 000 more with 
untested tumors (of which an estimated 8 000 would have been ER-positive). 
Adjuvant tamoxifen for one year, two years and five years produced proportional 
recurrence reductions of 21%, 29% and 47 %, respectively, during 10 years of follow-
up. The corresponding proportional mortality reductions were 12%, 17% and 26%, 
respectively (9). However, more than five years of adjuvant tamoxifen did not lead to 
any additional benefit in a Scottish study (95) and in the NSABBP B-14 study 10 
years of tamoxifen was in fact associated with more recurrences than five years of 
tamoxifen (96). Other trials are still ongoing to address the question of tamoxifen 
treatment beyond five years. 
 
According to the EBCTCG meta-analysis, the proportional mortality reductions were 
similar for women with node-positive and node-negative disease, but the absolute 
mortality reductions were greater in node-positive women. With five years of 
adjuvant tamoxifen treatment, the absolute improvements in 10-year survival were 
11% for node-positive and 6% for node-negative breast cancer patients. The 
proportional reductions in breast cancer recurrence and mortality appeared to be 
largely unaffected by other patient characteristics such as age or other treatment 
modalities given (9). 
 
In addition to its efficacy in metastatic and early breast cancer, tamoxifen has also 
been shown to prevent invasive breast cancer (97). Five years of adjuvant tamoxifen 
produced a proportional reduction in contralateral breast cancer of 47% in breast 
cancer patients (9).  In a NSABBP B-24 trial 1 804 women with ductal carcinoma in 
situ  (DCIS) were randomly assigned to either tamoxifen or placebo for five years 
after lumpectomy and radiation therapy. Women in the tamoxifen group had 
significantly fewer breast-cancer events at five years than did those on placebo (8% v. 
13%) (98).  
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 Other SERMs 
 
Other SERMs in clinical use today include toremifene, raloxifene and fulvestrant. 
Raloxifene and fulvestrant are not used in the adjuvant setting in early breast cancer.  
 
Preclinical studies suggest that toremifene has antiestrogenic and estrogenic effects 
similar to those of tamoxifen. However, toremifene may have a lower estrogenic-to-
antiestrogenic ratio than tamoxifen  (99). Toremifene has shown comparable efficacy 
to tamoxifen both in the treatment of metastatic breast cancer (100, 101) and as 
adjuvant therapy (102, 103) in postmenopausal women. In the adjuvant trial 
conducted by the Finnish Breast Cancer Group (FBCG) toremifene 40 mg/day was 
compared with tamoxifen 20 mg/day, both given for three years to postmenopausal 
women with early breast cancer. The DFS or OS did not differ between the treatment 
groups, but a trend towards an improved survival for patients on toremifene was seen 
in a subgroup of ER-positive patients (102). Another adjuvant trial (IBCSG 12-93 and 
14-93) compared toremifene 60 mg/day with tamoxifen 20 mg/day in peri- and 
postmenopausal patients; most patients had also received adjuvant chemotherapy. The 
DFS and OS were similar in the two treatment groups, also in the ER-positive cohort 
(103) (Table 2). 
 
Raloxifene is a selective estrogen receptor modulator that binds to ER to 
competitively block estrogen-induced DNA transcription in the breast and 
endometrium (104) and exhibits beneficial estrogenic effects on the bone and lipid 
metabolism (105). In animal studies, raloxifene inhibits estrogen-stimulated growth of 
mammary cancers (106). Raloxifene is used mainly in the prevention or treatment of 
postmenopausal osteoporosis (107) but it also reduces the incidence of ER-positive 
breast cancer (108). 
 
Fulvestrant is the first of a new type of ER antagonist that downregulates the ER and 
is devoid of the partial agonist properties of tamoxifen when tested in laboratory 
models (108). Randomized trials have showed fulvestrant (250 mg, once monthly via 
intramuscular injection) to be at least as effective as the aromatase inhibitor 
anastrozole for the treatment of postmenopausal women with hormone receptor–
positive advanced breast cancer progressing on prior endocrine therapy (110, 111). In 
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 a trial comparing fulvestrant versus tamoxifen as first line treatment in advanced 
breast cancer, fulvestrant demonstrated similar efficacy as tamoxifen in those patients 
with hormone-receptor positive tumors (112).  
 
5.2.2.2 Aromatase inhibitors 
 
The aromatase enzyme is critically responsible for the conversion of androgen 
precursors into estrogen. The rationale for using aromatase inhibitors is to decrease 
the levels of both circulating estrogen and intratumoral estrogen by inhibiting the 
conversion of androstenedione into estrogen. In premenopausal women, the primary 
site of aromatase activity and hence of estrogen synthesis, is the ovary. Aromatase 
inhibitors are ineffective in suppressing such premenopausal ovarian aromatase 
activity (113) and may even provoke an ovarian hyperstimulation syndrome (114). In 
postmenopausal women, on the other hand, they are effective in suppressing 
extraovarian sites of aromatase enzyme activity (i.e. adipose tissue, muscle, liver, 
breast tumor). This peripheral aromatization in postmenopausal women is almost 
completely inhibited by administration of the third-generation inhibitors (115, 116). 
There are two classes of third-generation oral aromatase inhibitors: reversible 
nonsteroidal inhibitors, such as anastrozole and letrozole (117) and irreversible 
steroidal inactivators, exemplified by exemestane (118).  
 
The third generation aromatase inhibitors have shown superior efficacy over 
tamoxifen as first-line treatment of postmenopausal women with advanced hormone-
sensitive breast cancer (77-79). Exemestane can also benefit some patients after 
failure of nonsteroidal aromatase inhibitors such as anastrotzole or letrozole  (119). 
There are insufficient data to recommend one aromatase inhibitor over another. A 
randomized unblinded trial compared the efficacy of anastrozole and letrozole in 
metastatic breast cancer and showed no significant difference between the two agents 
in time to progression (120).  
 
Few phase III randomized, adjuvant trials have assessed the third-generation 
aromatase inhibitors in comparison with tamoxifen or to a placebo following some 
years of tamoxifen therapy in postmenopausal patients with early breast cancer (Table 
2). The ATAC trial evaluated anastrozole alone or in combination with tamoxifen 
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 compared with tamoxifen alone, as a five-year adjuvant treatment (80, 81, 121). The 
BIG 1-98 trial randomized the patients to receive either tamoxifen for five years, 
letrozole for five years, tamoxifen for two years followed by letrozole for three years 
or letrozole for two years followed by tamoxifen for three years (86). In both of these 
trials, DFS was superior in the aromatase inhibitor arm as compared to tamoxifen, but 
so far, no significant difference in OS has emerged between the treatment groups 
(121, 86). Also switching patients on adjuvant tamoxifen to aromatase inhibitor 
(anastrozole or exemestane) seems to decrease the risk of relapse (84, 85, 122-124). 
Furthermore, aromatase inhibitor therapy after the standard five-year tamoxifen 
treatment seems beneficial. Letrozole, when started after the completion of five-year 
tamoxifen therapy, improved DFS when compared with placebo and even an OS 
advantage was seen in the subset of node-positive women (83, 84).  
 
Until recently, tamoxifen has been considered as a first choice for adjuvant treatment 
of postmenopausal hormone-receptor positive breast cancer and aromatase inhibitors 
have been recommended only for patients in whom tamoxifen is contraindicated or 
not tolerated (48). The updated ASCO Technology assessment on the use of 
aromatase inhibitors, however, states that optimal adjuvant hormonal therapy for a 
postmenopausal woman with receptor-positive breast cancer includes an aromatase 
inhibitor either as initial therapy or after treatment with tamoxifen (125). At present, it 
is not known whether tamoxifen pre-primes the cells to make them sensitive to 
aromatase inhibitors and thus, it is not known whether tamoxifen followed by an 
aromatase inhibitor is better than aromatase inhibitor as initial treatment. The findings 
of the major adjuvant trials comparing tamoxifen and other endocrine therapies in 
postmenopausal patients are summarized in Table 2. 
 
In addition, preliminary data suggests that there might be special subgroups of 
patients who derive most benefit from aromatase inhibitors. A subgroup analysis of 
the ATAC trial showed that the women with ER-positive but PR-negative breast 
cancer might derive greater benefit from initial therapy with an aromatase inhibitor 
(126). Two neoadjuvant studies have reported better RRs for aromatase inhibitors as 
compared with tamoxifen in patients with breast cancer overexpressing HER-2-neu 
(127, 128).  
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 In conclusion, adjuvant therapy with aromatase inhibitors seems to improve DFS as 
compared to tamoxifen in all major adjuvant trials but an OS advantage has so far 
emerged only in one trial of continued letrozole after five-year tamoxifen (node-
positive subset). If the benefits of aromatase inhibitors can be confirmed in the long 
term, they will challenge the place of tamoxifen as the gold standard for adjuvant 
therapy in hormone-sensitive postmenopausal breast cancer. For the premenopausal 
patients, tamoxifen remains the recommended endocrine therapy.   
 
Table 2. Major adjuvant trials comparing tamoxifen and other endocrine 
therapy regimens in postmenopausal breast cancer  
Trial n Treatment 
 
Patients Follow-up DFS  
FBCG 1480 
(899) 
TAM 3 years v. 
TOR 3 years 
N+ 100% 
ER+ 62% 
3.4 years 66% 
70% 
IBCSG 12/14-93  1035 TAM 5 years v. 
TOR 5 years 
N+ 100% 
ER+ 75% 
5.5 years 69% 
72% 
ATAC 9366 TAM 5 years v. 
ANA 5 years 
N+ 40% 
ER/PR+ 84% 
4 years  
(5 years) 
85% 
87%* 
BIG 1-98  
 
8023 TAM 5 years v. 
LET 5 years v. 
N+ 41% 
ER/PR+ 100% 
3 years 81% 
84%* 
IES 4742 TAM 5 years v. 
TAM+EXE 5 years 
N+ 44% 
ER+ 81% 
2.5 years 87% 
92%* 
ABCSG 8+ 
ARNO 95 
3224 TAM 5 years v. 
TAM+ANA 5 years 
N+ 26% 
ER/PR+ 81% 
2.3 years 93% 
96%* 
ANA=anastrozole, ER+=ER-positive, EXE=exemestane, DFS=disease-free survival, LET=letrozole, 
n=number of patients, N+=node-positive, PR+=PR-positive, TAM=tamoxifen, TOR=toremifene, 
*=significant difference 
 
5.2.2.3 Ovarian ablation 
 
Ablation of the ovaries has been used in the treatment of breast cancer for more than 
100 years and its value as an adjuvant treatment for premenopausal women has been 
clearly demonstrated by the Early Breast Cancer Trialists’ Collaborative Group 
(EBCTCG) meta-analysis (87). Ovarian ablation consists of removal of the main 
source of estrogen synthesis in premenopausal women. Traditionally ovarian ablation 
has been achieved by surgery or irradiation. The failure rate of pelvic irradiation in 
achieving amenorrhea may be rather high (129). If successful, it produces irreversible 
ovarian suppression like surgical oophorectomy with the possibility of serious long-
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 term effects. More recently, luteinizing hormone releasing hormone (LHRH) agonists, 
that suppress estradiol concentrations to postmenopausal levels, have become more 
popular at least in clinical trials. The benefit of the LHRH agonists is that the ovarian 
suppression achieved is potentially reversible (130). 
 
Young age is considered as an independent adverse prognostic factor in early breast 
cancer (43). Young premenopausal breast cancer patients with ER-positive tumors 
treated with adjuvant CMF chemotherapy have a particularly unfavorable prognosis if 
they do not achieve amenorrhea (131). It has been postulated that proportion of the 
benefit of adjuvant breast cancer chemotherapy in premenopausal receptor-positive 
women is mediated through a castration effect, as chemotherapy-induced ovarian 
failure is associated with better DFS (132, 133). 
 
According to the EBCTCG meta-analysis (n=3456), ablation of functioning ovaries in 
women aged less than 50 years with early breast cancer significantly improves long-
term survival, at least in the absence of chemotherapy (87). In women aged less than 
50 years when randomized, most of whom would have been premenopausal at 
diagnosis, the 15-year OS was highly significantly improved in those undergoing 
ovarian ablation (52% v. 46%), as was also recurrence-free survival (45% v. 39%). 
The proportional reduction in the risk of recurrence was 19%. The benefit was 
significant both for those with node-positive and for those with node-negative disease. 
In women aged 50 years or over when randomized, most of whom would have been 
perimenopausal or postmenopausal, no significant improvement in survival was noted 
(87, 134).  
 
The benefits of ovarian ablation might well be lessened by the presence of 
polychemotherapy, as such chemotherapy induces ovarian dysfunction in many 
premenopausal women (87, 135). In the EBCTCG meta-analysis, the risk reduction 
produced by ovarian ablation appeared to be nonsignificant in the presence of 
chemotherapy (i.e., in trials of ablation plus chemotherapy versus the same 
chemotherapy alone) and, in these trials, the benefits appeared to be greater in women 
with ER-positive primary tumours. These comparisons were, however, based on 
numbers too small to be statistically significant (87, 134). 
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 Adjuvant treatment with ovarian ablation seems to have comparable efficacy to CMF 
chemotherapy. In the few randomized trials comparing ovarian ablation and CMF 
chemotherapy, no difference in DFS has been noted between these treatment 
modalities (136, 137). However, patients with ER-negative tumors seem to fare better 
with CMF (137, 138) and those with ER-positive equally (138) or better (137) with 
ovarian ablation. Also the efficacy of combined endocrine treatment with ovarian 
ablation and tamoxifen has been compared to CMF chemotherapy in hormone-
receptor positive early breast cancer. In one study, DFS was significantly better in the 
ovarian ablation plus tamoxifen group as compared to CMF alone (139), while in 
another study, DFS did not differ between the combined endocrine treatment and 
chemotherapy groups (140).  
 
The question of whether adding ovarian ablation to adjuvant chemotherapy improves 
outcome, has been assessed in a few trials. Adding ovarian ablation to adjuvant CMFp 
(cyclophosphamide, methotrexate, 5-fluorouracil, prednisone) chemotherapy did not 
improve DFS as compared to this chemotherapy alone, even for patients with ER-
positive tumors (141). Similarly, CMF chemotherapy with goserelin yielded similar 
DFS as compared to either modality alone in patients with ER-positive early breast 
cancer (142). Adding ovarian ablation (goserelin) to an anthracycline-containing 
chemotherapy had no significant effect on survival when compared to chemotherapy 
alone. However, a trend towards DFS benefit with goserelin was seen in a subgroup 
of women under 40 years of age and who were not amenorrheic after chemotherapy 
(143). 
 
Also, the potential benefits of adding combined endocrine treatment with both ovarian 
ablation and tamoxifen to adjuvant chemotherapy have been studied. Adding 
goserelin and tamoxifen to an CMF/anthracycline-containing chemotherapy did not 
affect OS as compared to chemotherapy alone, though the risk of relapse was reduced 
in the combined modality group (144). Moreover, ovarian ablation in addition to 
tamoxifen and CMF chemotherapy offered no survival benefit over tamoxifen and 
CMF chemotherapy (145). 
 
The studies described above demonstrate the efficacy of ovarian ablation as adjuvant 
therapy for premenopausal women. In those women with endocrine-responsive 
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 disease, ovarian ablation with (139) or without tamoxifen (138) seems to be at least as 
effective as CMF chemotherapy alone. On the other hand, adding ovarian ablation to 
chemotherapy has not demonstrated any survival benefit over chemotherapy alone 
(141, 142) with the possible exception of women under 40 years of age and who do 
not achieve amenorrhea after chemotherapy (143).  
 
Anthracycline-containing chemotherapy plus tamoxifen or tamoxifen alone are 
nowadays the most commonly used adjuvant therapies in hormone-receptor positive 
breast cancer. The fact that the studies described above lack an anthracycline-
containing chemotherapy plus tamoxifen arm for comparison has lead to uncertainty 
about the position of ovarian ablation in clinical practice. Long-term side effects, 
mainly in young women, are still a significant issue when ovarian ablation is offered. 
As LHRH agonists produce a reliable but reversible suppression of ovarian estrogen 
production they represent a beneficial therapeutic option for premenopausal patients 
with hormone-sensitive disease. 
 
5.2.2.4 Side effects of different endocrine therapy regimens 
 
While tamoxifen has long been the gold standard of adjuvant endocrine therapy with 
well-documented side effects, significant differences in the safety profiles between 
various SERMs and aromatase inhibitors have now become evident during the follow-
up of the studies described above. 
 
Both tamoxifen and raloxifene have increased the rates of venous thromboembolic 
events in prevention and adjuvant trials (97). According to a large meta-analysis, 
(n=52 929 patients), tamoxifen is associated with a significantly increased risk of 
stroke and pulmonary embolus (146). The venous complications may be less frequent 
among toremifene-treated patients (102). The incidence of thromboembolic events is 
significantly lower in patients treated with adjuvant aromatase inhibitors than with 
tamoxifen (86, 121, 124). Arthralgia is more common with aromatase inhibitor than 
tamoxifen use (121, 124). 
 
The use of tamoxifen in postmenopausal women is associated with a 2–3 fold 
increased risk of endometrial cancer (146). No such excess of endometrial cancers has 
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 been seen with the use of toremifene though far less patients have been treated with 
toremifene than with tamoxifen (147). Raloxifene has not been associated with an 
increased rate of endometrial carcinoma compared with placebo (108, 148). 
Anastrozole, an aromatase inhibitor with the longest adjuvant tolerability data, does 
not seem to increase the risk of endometrial cancer (121).  In general, gynecologic 
symptoms such as vaginal bleeding (86, 121) and discharge (121) are more common 
with tamoxifen than with aromatase inhibitor use.  
 
The effects of endocrine therapies on bone and lipid metabolism are discussed in more 
detail in chapters 6 and 8. 
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 6. LONG-TERM EFFECTS OF ADJUVANT TREATMENTS ON BONE 
METABOLISM 
 
6.1 Bone structure and metabolism 
 
Bone in adults consists of an outer part called cortical or compact bone and an inner 
part named cancellous or trabecular bone. Cortical bone is hard and dense and is 
found in flat bones, the shafts of long bones and as a thin covering over all other 
bones. Trabecular bone tissue is located inside the ends of long bones and in short 
bones such as vertebral bodies. The hollow centre of long bones contains yellow bone 
marrow, which consists predominantly of fat cells (149, 150). 
 
Bone is composed of mineral, organic matrix and bone cells. The organic matrix 
consists predominantly of collagen fibers and the mineral consisting of calcium and 
phosphate is deposited on these collagen fibers (149, 150). Bone contains four cell 
types, osteoblasts, osteocytes, osteoclasts and bone lining cells (151). Bone is 
constantly being turned over in a process called remodeling employing predominantly 
two cell types, osteoblasts and osteoclasts. During remodeling, new bone is being 
formed by the osteoblasts and old bone is being dissolved by the osteoclasts. 
Osteoblasts secrete both the type I collagen and the non-collagenous proteins of 
organic matrix and they regulate the mineralization of this matrix. Osteoclasts resorb 
bone by attaching themselves to the matrix and secreting enzymes that digest the 
matrix and dissolve the bone mineral (149). 
 
Normally the amount of bone formed equals the amount destroyed. In osteoporosis, 
this “coupling” between bone formation and resorption is disturbed. As a result, more 
bone is being resorbed than formed resulting in negative balance (149). Osteoporosis 
is a disorder of bone turnover where the total amount of bone tissue decreases, but its 
composition remains normal (152). This is in contrast to osteomalacia, where the 
amount of bone tissue is normal but its mineralization is defective. Osteoporosis is 
first seen in cancellous bone where the bone turnover is far more active than in the 
cortical bone. The main contributory factors in the development of osteoporosis are a 
too little peak bone mass formed during adolescence and the continuous loss of bone 
in later decades.  
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 Postmenopausal bone loss is a consequence of defective bone remodeling stemming 
from estrogen deficiency. The withdrawal of sex steroids leads to bone loss because 
bone formation, albeit enhanced, is unable to keep pace with an even more abundant 
stimulation of osteoclastic bone resorption (153), a phenomenon known as 
uncoupling. The mechanism driving this uncoupling is central to the pathogenesis of 
postmenopausal osteoporosis but remains poorly understood. 
 
Calcium homeostasis in the body is set by an interaction between the blood calcium 
and its target organs: bone, intestine and the kidneys. As calcium is the principal 
mineral of the bone, disturbances in the blood calcium levels will ultimately affect  
bone metabolism (149). Physiological regulation of blood calcium is maintained by 
the parathyroid hormone (PTH). Secretion of PTH by the parathyroid glands is 
inversely related to ionized serum calcium. PTH stimulates bone resorption and 
increases renal calcium reabsorption. It also increases the hydroxylation of 25-
hydroxy-vitamin D to 1,25-dihydroxy-vitamin D (calcitriol) in the kidney. Calcitriol, 
in turn, increases absorption of calcium from the gut but also independently stimulates 
bone resorption (154). Calcium deficiency due to dietary factors or decreased calcium 
absorption by the intestine as well as vitamin D deficiency may thus induce bone loss 
and contribute to the development of osteoporosis (149). 
 
6.2 Methods of examining bone metabolism 
 
6.2.1 Bone mineral density (BMD) 
 
Single (SXA) and dual X-ray absorptiometry (DXA) are used to assess mineral 
content of the entire skeleton and that of specific sites. Bone mineral content is the 
amount of mineral in the specific site scanned and, when divided by the area 
measured, can be used to derive a value for BMD (155). Other techniques used to 
assess bone density are those utilizing ultrasound (broad-band ultrasound attenuation 
and ultrasound velocity at the heel) and computed tomography. Today, DXA is 
regarded as the gold standard for diagnosis of low bone mass and osteoporosis (156). 
The recommended sites for diagnosis are the proximal femur and the lumbar spine. 
(157). The presence of osteomalacia, osteoarthritis or even aortic calcification is a 
potential source of error in the DXA measurements (158). 
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 BMD measurements are usually given as standard deviations (SDs) from the mean. In 
relation to the bone mass of 30-year-old subjects of the same sex, this SD value is 
expressed as a T score, and in relation to an age-matched population, as a Z score 
(155). A World Health Organization (WHO) expert panel proposed that women with a 
T score of -2.5 SD below the young adult mean value be considered osteoporotic and 
those with T scores between -1 and -2.5 SD be considered osteopenic (159). 
 
6.2.2 Biochemical markers of bone turnover 
 
Biochemical markers of bone turnover are substances in blood and urine that are 
indicative of events occurring during the bone remodeling cycle. They are divided 
into markers of bone formation and markers of bone resorption and reflect the relative 
activity of osteoblasts and osteoclasts, respectively (160). The most common markers 
of bone formation are osteocalcin, bone alkaline phosphatase (AFOS) and 
aminoterminal propeptide of type I collagen (PINP). Markers of bone resorption 
include pyridinoline, deoxypyridinoline, hydroxyproline, cross-linked 
aminotelopeptide of type I collagen (NTX), cross-linked carboxytelopeptide of type I 
collagen (CTX) and cross-linked carboxy-terminal telopeptide of type I collagen 
(ICTP). Markers of bone turnover demonstrate significant day-to-day and circadian 
variability (161, 162).  
 
Under most circumstances, the levels of resorption and formation markers change in 
the same direction (i.e., increase or decrease). An increase of bone turnover occurs 
during the menopause and is reflected by elevation of bone markers already during the 
perimenopause (163, 164). During hormone replacement treatment these markers 
decrease to the premenopausal level (165, 166). Similarly, treatment with most 
antiresorptive agents, such as bisphosphonates and SERMs, results in rapid and large 
reductions in markers of bone resorption coupled with more modest reductions in 
markers of bone formation (167). 
 
High levels of bone turnover markers predict postmenopausal bone loss (168) and 
seem to be an independent risk factor for fracture (169, 170). Thus, much interest has 
been focused on the potential of predicting treatment efficacy with bone turnover 
markers. The early bone marker changes during hormone replacement therapy (171) 
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 and bisphosphonate treatment (172, 173) seem to predict long-term effects on bone 
mass, even though variability of the marker changes decreases their predictive value 
in individualized therapy. Among women treated with antiresorptive agents such as 
raloxifene or bisphosphonates, greater short-term reductions in bone turnover are 
associated with fewer subsequent fracture events (174, 175). 
 
One potential use of biochemical markers of bone turnover is the prediction of 
antifracture efficacy on the basis of pre-treatment levels of biochemical markers. The 
findings in this area are conflicting, though. The nonvertebral fracture risk reduction 
with alendronate treatment has been shown to be greater among those women with 
high levels of bone formation markers before therapy as compared to those with low 
pre-treatment levels (176). On the contrary, the efficacy of risedronate to reduce 
vertebral fractures in women with postmenopausal osteoporosis seems to be largely 
independent of pretreatment bone resorption rates (177). 
 
In conclusion, clinical questions that might be answered by bone turnover markers 
include diagnosing osteoporosis, identifying "fast bone losers" and patients at high 
risk of fracture, selecting the best treatment for osteoporosis, and providing an early 
indication of the response to treatment. Additional information is needed to define 
specific situations and cut points to allow marker results to be used with confidence in 
making decisions about individual patients (178). 
 
6.2.2.1 PINP and ICTP as markers of bone turnover 
 
PINP is a marker of bone formation intended to reflect the synthesis of type I collagen 
(179). Type I collagen is the major structural organic component of bone tissue and is 
secreted into the extracellular matrix as an extended precursor called procollagen with 
amino and carboxy-terminal propeptide domains (termed PINP and PICP, 
respectively). Before incorporation into the bone matrix, both propeptides are cleaved 
by specific proteinases and are released into the circulation, where they can be 
measured (180). 
 
Serum concentrations of PINP increase after surgical (181) or chemotherapy-induced 
menopause (182). PINP levels increase in postmenopausal osteoporosis (183). During 
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 hormone replacement therapy (184) and treatment with the bisphosphonate clodronate 
(182) the PINP levels decrease reflecting the reduced bone turnover. Moreover, a 
decrease in PINP observed during raloxifene therapy in postmenopausal women with 
osteoporosis seems to predict a reduction in the vertebral fracture risk (185). 
 
ICTP is a degradation product of mature type I collagen. Its serum concentration 
reflects type I collagen breakdown (186). ICTP has been reported to increase in cases 
of elevated bone matrix degradation, as in patients with osteolytic metastases (187). 
The results of ICTP as a resorption marker in postmenopausal osteoporosis or as an 
indicator of efficacy of antiresorptive treatment have been conflicting (182,188, 189). 
 
6.3 Chemotherapy and bone metabolism 
 
Women with breast cancer are at increased risk for osteoporosis as compared with 
women in general (190). In a majority of premenopausal breast cancer patients, 
adjuvant chemotherapy causes an early menopause and a rapid bone loss that may 
increase the risk of osteoporosis later in life (11, 12, 25, 26). Although the incidence 
of vertebral and hip fracture is unknown in breast cancer patients who develop ovarian 
failure, early menopause is a risk factor for osteoporosis in other settings.  
 
The incidence of adjuvant chemotherapy-induced amenorrhea varies from 26% to 
89% depending on the drug combination used (191). Generally, the higher the 
cumulative dose of cyclophosphamide, the higher the observed incidence of 
menopause (192). Two thirds of premenopausal women experience amenorrhea with 
the adjuvant regimen CMF (11), while rates of amenorrhea associated with 
anthracycline therapy show significant variation among studies (11, 60, 68). Women 
most prone to develop ovarian failure and early menopause are those in their 40s, 
while younger women have better preservation of menstruation after adjuvant 
chemotherapy (11, 193, 194). 
 
The changes in BMD are strongly associated with menstrual function after 
chemotherapy. Women who develop chemotherapy-induced ovarian failure undergo 
accelerated and highly significant bone mineral loss while those who continue to 
menstruate have only minimal changes in BMD (26, 195). In a study by Saarto et al, 
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 the change in BMD at 12 months in patients with chemotherapy-induced amenorrhoea 
was -6.8% in the lumbar spine and -1.9% in the femoral neck, respectively (26). In a 
study by Shapiro et al, the first annual BMD decrease in patients with chemotherapy-
induced amenorrhoea was 7.7% in the lumbar spine and 4.6% in the femoral neck, 
respectively (195). A similar rapid bone loss has also been demonstrated after surgical 
ovarian ablation (oophorectomy) (24). Significant increases in bone formation 
markers serum osteocalcin and bonespecific AFOS were observed in the women who 
developed chemotherapy-induced ovarian failure at six and 12 months. Among those 
who retained menstrual function, significant increases in these markers were observed 
at six months; however, between six and 12 months the markers declined (195). 
 
In addition to the risk for early menopause induced by chemotherapy, some 
chemotherapeutic agents used in the treatment of breast cancer may have a direct 
adverse effect on BMD. Methotrexate increases bone resorption in vivo as assessed by 
both increases in urinary hydroxyproline levels and histomorphometry  (196). Severe 
osteoporosis with fractures has been reported after high-dose and long-term 
methotrexate treatment (197).  Doxorubicin has been observed to cause a decrease in 
the trabecular bone volume (198).  
 
Breast cancer itself may predispose to osteoporosis. Patients with cancer but without 
bone metastases show increased bone resorption as indicated by biochemical markers 
of bone turnover (198). In a study by Kanis et al, a high incidence of vertebral fracture 
was noted in women with breast cancer but without evident bone metastases (199).  
 
6.4 Endocrine therapy and bone metabolism 
 
Data on the effects of tamoxifen on bone turnover markers are limited. Decreases in 
the urinary excretion of the bone resorption (pyridinoline, deoxypyridinoline, 
hydroxyproline and NTX) and formation markers (osteocalcin and PINP) during 
tamoxifen treatment have been demonstrated in a few studies (200, 201). These 
findings probably reflect decreased bone remodelling similar to that observed with 
oral estrogen.  
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 The effects of tamoxifen on BMD have been studied in both postmenopausal breast 
cancer patients and healthy postmenopausal women with concordant results. The data 
accumulated to date confirm that in postmenopausal women tamoxifen significantly 
decreases the loss of BMD in the lumbar spine and to a somewhat lesser degree at the 
femoral neck. Tamoxifen at least prevents bone loss in the lumbar spine or even 
increases the lumbar spine BMD (34-38, 200-205). In most trials, tamoxifen 
preserved or even increased BMD also in the femoral neck (35, 37, 38, 200, 202- 204) 
or had no effect (37). The positive effect of tamoxifen on BMD has been shown to last 
over the treatment period of five years (201, 205). However, a rapid decrease of 4.8% 
in the lumbar spine BMD was noted when BMD was measured one year after the 
cessation of five-year adjuvant tamoxifen (205).   
 
There is some data on the effects of tamoxifen on the risk of fracture. A large placebo-
controlled study using tamoxifen in the prevention of breast cancer in more than 13 
000 patients at high risk showed a nonsignificant reduction of about 20% in the 
overall incidence of spine, Colles and hip fracture (206). In an adjuvant study on 1 
716 postmenopausal women with breast cancer the femoral fracture rate was not 
decreased among tamoxifen users (207). In a randomized study on 140 
postmenopausal women with early breast cancer, no significant difference in the 
fracture rate between the tamoxifen and placebo groups was noted (201). 
 
While tamoxifen prevents bone loss in postmenopausal women, the effects may be 
opposite for premenopausal women. Powles et al studied the effects of tamoxifen on 
BMD in 179 pre- and postmenopausal healthy women who participated in a placebo-
controlled tamoxifen chemoprevention trial. In premenopausal women, both lumbar 
spine and femoral neck BMD decreased progressively in tamoxifen users. In 
accordance of prior studies, in postmenopausal patients tamoxifen increased the 
lumbar spine and femoral neck BMD compared with a nonsignificant loss for women 
on placebo (38).  Thus, in premenopausal women, tamoxifen seems to act as an 
antiestrogen on bone tissue, probably competing with the endogenous estradiol and 
resulting in bone loss. 
 
The effects of another SERM toremifene on bone have been less extensively studied. 
Similarly to tamoxifen, the urinary excretion of bone resorption markers decreases 
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 during toremifene treatment reflecting reduced bone turnover (200). Adjuvant 
toremifene at a dose level of 60 mg/day prevented bone loss in postmenopausal breast 
cancer patients (202) while toremifene 40 mg/day failed to do so (203). 
 
Raloxifene is the first SERM approved for the prevention of osteoporosis and 
reduction of new vertebral fractures in postmenopausal women with osteoporosis. 
Raloxifene decreases bone loss in healthy postmenopausal women (208), women with 
osteopenia (209) and women with osteoporosis (107). The increase in BMD and 
decrease in biochemical markers of bone turnover noted in raloxifene treated patients 
compare well with those noted during estrogen treatment (210). The largest 
osteoporosis intervention trial so far randomized 7 705 postmenopausal women with 
osteoporosis to receive either raloxifene 60 mg or 120 mg or placebo. After three 
years of follow-up, raloxifene increased the BMD in the lumbar spine and femoral 
neck as compared to the placebo group. Moreover, raloxifene decreased the 
cumulative risk of new vertebral fractures but the risk of nonvertebral fractures was 
similar in the raloxifene and placebo groups  (107). The update at four years of 
follow-up did not significantly change these results (211). 
 
While the SERMs provide protection against bone loss in postmenopausal women, the 
aromatase inhibitors may reduce bone mineral density by decreasing estrogen levels. 
Estrogen deficiency in turn may lead to osteoporosis (212). Recent studies have 
shown that both anastrozole and letrozole increase bone resorption (213-215). In the 
ATAC trial comparing adjuvant anastrozole and tamoxifen, tamoxifen had a slightly 
positive effect on BMD while anastrozole had a negative effect on BMD. Also 
fractures were significantly more common with anastrozole than with tamoxifen 
during the follow-up of 68 months (11.0% v. 7.7%, respectively). The greatest 
increase in fractures on anastrozole treatment seemed to be in the spine while no 
increase in hip fractures was seen (121, 216). A four-group trial evaluating adjuvant 
tamoxifen, letrozole or a sequential combination of these (BIG 1-98) also reported 
significantly more fractures with patients on letrozole as compared to tamoxifen 
(5.8% v. 4.1%, respectively) (86). In a MA-17 adjuvant study on letrozole after five 
years of tamoxifen, newly diagnosed osteoporosis was significantly more common 
among women on letrozole as compared to those on placebo. No significant 
difference in fracture rates between the groups emerged during the short follow-up of 
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 2.5 years (83, 84). In the IES adjuvant study on exemestane, a trend towards a higher 
incidence of reported fractures in the exemestane group as compared to the tamoxifen 
group was reported (85, 124).  
 
Ovarian ablation with LHRH analogs causes a sudden decline in estrogen levels and 
this chemical castration in turn leads to a rapid decrease in BMD (217). Both bone 
resorption and formation markers increase during the treatment of premenopausal 
women with LHRH agonist (217). As suggested in the preclinical setting (212), 
tamoxifen seems to partially counteract the demineralising effects of LHRH analogs. 
A Swedish study randomized premenopausal women with early breast cancer to 
receive goserelin alone, goserelin plus tamoxifen or tamoxifen alone for two years. 
The loss in total body BMD was greatest in women receiving goserelin alone, while 
tamoxifen plus goserelin and tamoxifen alone resulted in smaller declines in BMD. 
Though, one year after cessation of treatment, the goserelin alone group showed a 
partial recovery from the bone loss (219). 
 
The effects of adjuvant treatments on BMD and fracture risk are summarized in Table 
3. 
 
Table 3. Effects of adjuvant treatments on bone mineral density (BMD) and 
fracture risk in postmenopausal breast cancer patients 
 Chemotherapy 
 
Tamoxifen Toremifene Anastrozole Letrozole  Exemestane 
 
 
 
BMD 
 
 
         ↓↓* 
 
 
        ↑↑ 
        
 
 
        ↑ 
 
 
        ↓↓    
 
 
       ↓↓ 
 
 
        ↓   
 
Fracture risk 
 
         NE* 
 
        ↓ 
 
        NE 
 
        ↑↑ 
 
       ↑↑ 
 
        ↑ 
       
↓ decrease (trend), ↓↓ decrease (significant), ↑ increase (trend), ↑↑ increase (significant), NE not 
evaluated, * in chemotherapy-induced amenorrhea 
 
 
6.5 Osteoporosis 
 
Osteoporosis is defined as a disease characterized by low bone mineral mass, 
microarchitectural deterioration of bone tissue leading to increased bone fragility and 
consequent increase in fracture risk with minimal or no trauma  (220). Based on the 
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 World Health Organization criteria, about a third of postmenopausal white women 
have osteoporosis (221). Age is the most important risk factor for osteoporosis. Also 
the risk of osteoporotic fractures increases dramatically with aging. It has been 
estimated that a 50-year old white woman has a 40% risk of suffering a hip, Colles or 
vertebral fracture during her remaining lifetime (222). 
 
Strong risk factors of low bone density and osteoporosis for women include advanced 
age, previous fragility fracture, maternal family history of hip fracture, premature 
menopause, low body-mass index, corticosteroid therapy and some disorders 
associated with osteoporosis (hypogonadism, hyperparathyroidism, malabsorption 
syndromes, chronic renal failure, Cushing`s syndrome etc.)  (223). Other risk factors 
include smoking, high caffeine intake, physically inactive lifestyle and a low dietary 
intake of calcium and vitamin D. On the other hand, estrogen use, high body-mass 
index and late age at menopause seem to protect from osteoporosis (224). Regular 
weight-bearing exercise can conserve or improve BMD in peri- and postmenopausal 
women (225, 226). 
 
6.5.1 Treatment of osteoporosis – general 
 
Several therapeutic options with well-documented improvements in BMD and 
reductions in fracture risk are available to women for the prevention and treatment of 
postmenopausal osteoporosis. The bisphosphonates clodronate, etidronate, risedronate 
and alendronate, raloxifene, calcitonin and (hydroxylated) vitamin D all reduce 
vertebral fractures, while only alendronate and risedronate significantly reduce 
nonvertebral fractures (227).  
 
The majority of evidence for the efficacy of hormone replacement therapy (HRT) on 
BMD and fracture risk is based on case-control and cohort studies instead of 
randomized trials. Observational studies have indicated a significant decrease in the 
risk of hip fracture in HRT users (228, 229). The largest randomized, placebo-
controlled trial Women`s Health Initiative (WHI) including 16 608 postmenopausal 
women, demonstrated a significant increase in BMD and decrease in the risk of both 
vertebral and nonvertebral fracture in women receiving estrogen plus 
medroxyprogesterone as compared to those on placebo. However, an increased risk of 
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 cardiovascular disease and breast cancer was observed in the HRT users relative to the 
placebo arm (230). Among the 10 739 postmenopausal women randomized to either 
estrogen or placebo, estrogen alone also decreased the risk of hip fracture, but, in 
contrast to the estrogen plus progestin treatment, also insignificantly decreased the 
risk of breast cancer  (231). 
 
Risedronate and alendronate are third- and second generation bisphosphonates, 
respectively, approved for prevention and treatment of postmenopausal osteoporosis. 
Alendronate increases the BMD in postmenopausal osteoporosis and decreases the 
risk of both vertebral and nonvertebral fracture (232, 233). Similarly, risedronate has 
been shown to increase the BMD in postmenopausal osteoporosis and to decrease the 
risk of both vertebral and nonvertebral fracture (234, 235). They can be administered 
orally either daily or more conveniently once weekly as these dosing options are 
equally effective (236, 237).  
 
The first generation bisphosphonate, clodronate, has also demonstrated beneficial 
effects on BMD in patients with osteopenia or osteoporosis. Both continuous and 
cyclical regimens given orally or intravenously have resulted in significant increases 
in BMD, especially in the lumbar spine (29, 31, 32, 238-240). Clodronate has been 
shown to reduce the risk of vertebral fracture (32, 240). Another first generation 
bisphosphonate, etidronate, significantly increases BMD at the spine and hips and 
slightly reduces the rate of spinal fractures (241).  
 
As already discussed above, the SERM raloxifene increases the BMD, decreases the 
markers of bone turnover and decreases the risk of vertebral fractures as compared to 
placebo (107, 208).   
 
Calcitonin is a polypeptide hormone derived from salmon. Calcitonin increases the 
BMD in spine and reduces the risk of new vertebral fractures. However, calcitonin has 
not demonstrated an ability to lower the frequency of nonvertebral fractures (242). 
Calcitonin is available as an injection or a nasal spray. 
 
Teriparatide is a recombinant human parathyroid hormone analogue available as an 
injection. While other therapeutic agents for osteoporosis reduce bone resorption, 
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 intermittently administered teriparatide stimulates new bone formation by 
preferentially stimulating osteoblasts. Consequently, the effects on bone turnover 
differ dramatically from those observed with antiresorptive therapy. With teriparatide, 
bone formation markers rise quickly and remain elevated for the duration of treatment 
(243). After a brief delay, PTH therapy also increases markers of bone resorption. 
Teriparatide has been shown to increase bone mineral density and to significantly 
reduce the risk of vertebral and nonvertebral fracture (244).  
 
Supplementation with (calcium and) vitamin D reduces risk of vertebral and probably 
also nonvertebral fractures (245, 246). Although the evidence from clinical trials 
demonstrates that vitamin D could prevent fractures, there is a wide variability in the 
magnitude of this effect. Therefore, calcium and vitamin D supplements should not be 
considered an adequate intervention for fractures in high-risk women but rather as a 
standard supplement to other osteoporosis drug therapy. Vitamin D supplementation 
appears to even reduce the risk of falls among ambulatory or institutionalized older 
individuals possibly by increasing musculoskeletal function (247). 
 
6.5.2 Treatment of osteoporosis in women with a history of breast cancer 
 
Osteoporosis is first seen in cancellous bone (e.g. the vertebral bodies) where bone 
turnover is fast. Reflecting this, a high incidence of vertebral fracture has been noted 
in women with breast cancer (199). Breast cancer patients found to have osteoporosis 
based on BMD results (T-score –2.5 or lower) should have pharmacological therapy 
initiated with an agent demonstrated to have efficacy. There is currently insufficient 
evidence to recommend a particular agent in this category (248). Some remarks, 
however, can be made based on indirect evidence. 
 
All postmenopausal women, also those with a history of breast cancer, should be 
encouraged to maintain adequate calcium and vitamin D intake and sustain regular 
physical activity in order to help preserve BMD. Appropriate calcium intake ranges 
between 1000 and 1500 mg/day depending upon age, and appropriate vitamin D 
intake ranges between 400 and 800 IU/day (246). Regular weight-bearing exercise 
can conserve or improve BMD in postmenopausal women (225). 
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 Although raloxifene is approved for osteoporosis prevention and therapy, its use after 
five years of adjuvant tamoxifen therapy may not be advisable. Raloxifene is a 
SERM, and it has been suggested that the usage of another SERM tamoxifen beyond 
five years might worsen the prognosis of breast cancer. In the NSABBP B-14 study 
10 years of tamoxifen was associated with more recurrences than five years of 
tamoxifen (96). Moreover, raloxifene has been shown to stimulate tamoxifen-
dependent cancer cells in laboratory studies (249).  
 
Teriparatide has been associated with osteosarcoma development in animal studies 
(317). Though no cases of osteosarcoma have been observed in humans treated with 
teriparatide for osteoporosis, it is not recommended for use in women diagnosed with 
breast cancer (248, 250). 
 
According to the recent findings in the WHI trial, HRT with estrogen and progestin is 
associated with an increased risk of breast cancer (230). Estrogen therapy has long 
been contraindicated in women with a history of breast cancer because of the probable 
increases in the risk of recurrence and second primary breast cancers (251). Recently, 
a Scandinavian open randomized trial addressing the question whether HRT is safe 
for women with breast cancer history was terminated because of safety concerns. New 
breast cancer events were more common in the HRT group relative to placebo group 
(252). HRT should not be used in the treatment or prevention of osteoporosis in breast 
cancer survivors. 
 
Of the treatment options available for osteoporosis prevention and therapy, the 
bisphosphonates may seem most appropriate for women with a history of breast 
cancer. According to recent reviews they seem to be the most efficient drugs in the 
treatment of osteoporosis (227).  
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 7. BISPHOSPHONATE TREATMENT IN BREAST CANCER 
 
7.1 Bone metastasis – general 
 
The skeleton is the most common organ to be affected by metastatic breast cancer:  
around 70 percent of patients dying with breast cancer have bone metastases (253, 
254). Breast cancer patients with bone metastases alone tend to have a protracted 
disease course when compared to those with visceral and in particular liver 
metastases. The median survival in patients with liver metastases averages one year 
(355) while the median survival in patients with disease confined to the skeleton 
survive at least twice that long (253). For patients with breast carcinoma, good 
prognostic factors for survival after the development of bone metastases are low 
histologic grade, positive estrogen receptor status, bone disease at initial presentation, 
a long disease free interval, and increasing age.  Up to 20 percent of breast cancer 
patients with metastatic bone disease survive five years after the diagnosis of bone 
metastases (254). 
 
Paget first proposed the idea of “seed and soil” hypothesis in the pathophysiology of 
bone metastases more than one hundred years ago (256). Micrometastatic deposits of 
cancer (“seed”) access the bone via the bloodstream. The bone microenvironment 
contains several growth factors that encourage the growth of cancer cells. As the 
metastatic cells alter the regulatory mechanisms of bone, it becomes a more favorable 
“soil” for the development of metastases. The tumor cells release different growth 
factors and cytokines (e.g. parathyroid hormone-related peptide (PTHrP), interleukins 
IL-1 and IL-6, TGFa, TGFb and prostaglandins) that accelerate the osteoclast-
mediated bone resorption and lead to local erosion of the bone (257). In breast cancer, 
the main mediator causing osteolysis is probably PTHrP (258).  
 
Bone resorption in metastatic bone disease leads to pathological fractures, pain and 
hypercalcemia. Bone pain is the most common complication of metastatic bone 
disease, resulting from structural damage, periosteal irritation, and nerve entrapment. 
The increased bone destruction brings about a release of calcium from the skeleton to 
the bloodstream. Other mechanisms behind the hypercalcemia of malignancy include 
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 PTHrP- mediated increased reabsorption of calcium in the kidney and dehydration 
(259).  
 
7.2 Mechanism of action of the bisphosphonates 
 
Bisphosphonates are synthetic compounds characterized by a P-C-P (phosphate-
carbon-phosphate) structure, in contrast with their naturally occurring analogue, 
pyrophosphate, with a P-O-P (phosphate-oxygen-phosphate) sequence. Unlike natural 
pyrophosphate, bisphosphonates are resistant to breakdown by enzymatic hydrolysis 
(260). The negative charges on the two phosphate groups of the bisphosphonate 
nucleus give these compounds a high affinity for mineralized bone. Modification of 
one of the two side chains coupled to the central carbon atom determines the 
antiresorptive potency of the bisphosphonate. According to the structure of this side 
chain, the bisphosphonates can be divided into those resembling natural 
bisphosphonate or non-aminobisphosphonates (clodronate and etidronate) and to 
those with a nitrogen-containing side chain, aminobisphosphonates (pamidronate, 
alendronate, zoledronic acid, risedronate, ibandronate). Over the years, first, second 
and third generation bisphosphonates have been developed with increasing potency 
from generation to generation. They are used in medicine mainly to inhibit bone 
resorption in diseases like osteoporosis, Paget's disease and metastatic bone disease. 
The more potent aminobisphosphonates have demonstrated higher efficacy than the 
non-aminobisphosphonates in preclinical studies, but the possible clinical differences 
between these compounds have not been extensively studied  (261). 
 
Bisphosphonates inhibit bone resorption by a variety of mechanisms. The principal 
biologic effect appears to be the inhibition of osteoclast activity. When osteoclasts 
ingest bisphosphonate-containing bone, their cytoskeleton becomes disrupted and 
apoptosis of the osteoclasts is activated (260). The non-aminobisphosphonates act as 
analogues of ATP (adenosine triphosphate) and inhibit ATP dependent intracellular 
enzymes leading to apoptosis and death of the osteoclasts (262). The 
aminobisphosphonates, on the other hand, inhibit enzymes of the mevalonate pathway 
by disrupting the signalling functions of key regulatory proteins and lead to osteoclast 
apoptosis (263-265). Bisphosphonates also inhibit the development of osteoclasts 
from monocyte-precursors (266). The net effect of both non-aminobisphosphonates 
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 and aminobisphosphonates is inhibition of osteoclast function, which leads to a 
decrease in bone resorption  (150). It has also been suggested that bisphosphonates 
prolong the survival of osteoblasts (267). 
 
The bisphosphonates inhibit normal and ectopic calcification by disturbing the 
formation of calcium phosphate crystals (262). Reflecting this, the first generation 
bisphosphonate etidronate has been shown to cause osteomalacia in the early studies 
(268). More recently, bisphosphonates have been shown to inhibit matrix 
metalloproteinases (MMPs) that are involved in bone resorption and tumor invasion. 
They have also been found to inhibit the adhesion of tumor cells to the bone and to 
induce tumor cell apoptosis in vitro (269-271). Bisphosphonates have demonstrated 
direct antitumor activity against neoplastic cells especially in the bone, where 
bisphosphonates reduce skeletal tumor burden and increase tumor cell apoptosis in 
skeletal metastases (270, 272, 273). The effect of bisphosphonates on non-skeletal 
metastases is still controversial. Even an adverse effect on the development of non-
skeletal metastases by bisphosphonate therapy has been suggested in some preclinical 
studies (274, 275).   
 
The clinical pharmacology of bisphosphonates is characterized by low intestinal 
absorption, but highly selective localization and retention in bone. The bioavailability 
of an oral dose of a bisphosphonate is only 1% - 10%. Absorption is further 
diminished if oral bisphosphonates are given at mealtimes and especially with dairy 
products or iron supplements. Bone takes up most of the absorbed bisphosphonate, the 
remainder being rapidly excreted in the urine. The skeletal retention of 
bisphosphonates is very lasting, possibly life-long. However, the bisphosphonate 
deposited in the skeleton probably has little pharmacological activity once the 
administration is ceased (276). 
 
Bisphosphonate therapy is generally well tolerated. The probability of hypocalcemia 
is greater with the use of intravenous aminobisphosphonates and therefore 
supplementation with calcium (and vitamin D) is recommended (277). When 
bisphosphonates are administered intravenously, too rapid an infusion may lead to 
renal complications (277). Thus, infusion times less than two hours with pamidronate 
or less than 15 minutes with zoledronic acid should be avoided (248). Ibandronate is 
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 given via a one- to two-hour infusion (278).  In a study comparing intravenous 
pamidronate and zoledronic acid, six to 8 percent of breast cancer patients showed 
some deterioration of renal function during the first 12 months of bisphosphonate 
therapy (279).  Though the renal complications during bisphosphonate therapy are 
often mild and apparent only as transient increases in serum creatinine, there are 
limited data on the long-term renal safety of bisphosphonates. Few case reports have 
been published about the adverse renal consequences of prolonged, high-dose 
bisphosphonate administration (280, 281). Consequently, the serum electrolyte and 
creatinine levels should be monitored during bisphosphonate therapy (248).   
 
Gastrointestinal discomfort, nausea, dyspepsia, vomiting, diarrhea and even 
esophageal ulceration may accompany oral administration of bisphosphonates. In a 
large adjuvant clodronate study, especially diarrhea was significantly more common 
in clodronate users than in those on placebo (15% v. 7%, respectively) (282). 
Similarly, in a pooled analysis of two oral ibandronate trials in breast cancer patients 
with bone metastases, patients receiving ibandronate were twice as likely to 
experience adverse gastrointestinal events than those receiving placebo (283).  
 
The intravenous administration of the aminobisphophonates can induce transient flu-
like symptoms with fever, myalgia and arthralgia. These side effects occur primarily 
after the first infusion (284). Recently, an association between long-term 
aminobisphosphonate therapy and osteonecrosis of the jaws has been reported (285). 
Few ocular disturbances including scleritis have been described during pamidronate 
use (286). 
 
7.3 Bisphosphonate treatment in metastatic breast cancer 
 
At least 14 randomized placebo-controlled prospective studies have been published on 
the effects of bisphosphonates in patients with metastatic breast cancer. These include 
five studies on clodronate (287-291), five studies on pamidronate (292-296), three 
studies on ibandronate (278, 283, 297) and one on zoledronic acid (298). In addition, 
there is one study comparing the efficacy of zoledronic acid and pamidronate in 
patients with breast cancer (299). These studies show that bisphosphonates, in 
addition to hormone therapy or chemotherapy, reduce the risk of developing a skeletal 
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 event (pathological fracture, hypercalcemia, bone pain or need for palliative 
radiotherapy) and the skeletal event rate. As summarized in a recent Cochrane review, 
bisphosphonates also increase the time to skeletal event but have no effect on survival 
in women with advanced breast cancer and bone metastases (33).  
 
Oral bisphosphonates, including clodronate and ibandronate, may be self-
administered at home and thus do not acquire frequent hospital admissions. However, 
patient compliance may be compromised by the gastrointestinal toxicity of these oral 
agents (282, 283). Although oral bisphosphonates seem somewhat less effective than 
the intravenous remedies at least for the treatment of hypercalcemia (277), at present 
the data is insufficient to recommend one bisphosphonate over another in the 
treatment of skeletal metastases (248). No studies directly compare the effectiveness 
of oral and intravenous bisphosphonates in the prevention of skeletal complications. 
The one study comparing two intravenous bisphosphonates showed a lower risk of 
skeletal events with zoledronic acid than with pamidronate (299). 
 
In addition to the trials in patients with breast cancer and bone metastases mentioned 
above, there are three placebo-controlled trials (one on oral pamidronate, two on oral 
clodronate) examining the role of bisphosphonates in patients with advanced breast 
cancer but no bone metastases (302-304). No effect on the development of bone 
metastases was found in the pamidronate and the smaller clodronate study (302, 304). 
In the larger clodronate study, however, the total number of skeletal metastases was 
significantly lower with clodronate treatment than with placebo, but the number of 
patients developing bone metastases did not differ between the treatment groups 
(303). 
 
7.4 Adjuvant bisphosphonate treatment in breast cancer  
 
7.4.1 Effect on survival 
 
There are three randomized prospective controlled trials available on adjuvant 
bisphosphonate treatment in early stage breast cancer. These trials on oral clodronate 
provide conflicting data on the potential role of adjuvant bisphosphonates among 
patients with no evidence of distant metastases after definitive local surgery.  
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 The first trial conducted by Diel et al randomly assigned 302 women with node-
positive and node-negative primary breast cancer and a positive bone marrow aspirate 
for tumor cells to receive either clodronate 1600 mg/day for two years or no 
bisphosphonate. The type of adjuvant systemic therapy was selected in accordance 
with specific guidelines (hormonal therapy, chemotherapy, or both, or no systemic 
therapy). In the initial report, with a median follow-up of 36 months, the incidence of 
overall metastasis (13% v. 29%), bone metastasis (8% v. 17%), and visceral 
metastasis (8% v. 19%) was significantly lower in the clodronate group. At five years 
of follow-up, the incidence of bone metastases was still significantly lower in the 
clodronate group, but the extra-skeletal effect was no longer significant (305, 306). 
Quite recently, the investigators provided an update of their initial report after an 
extended follow-up of 103 months. Although the incidence of osseous and visceral 
metastases was now similar in both groups, the OS was still significantly better in the 
clodronate group (307). 
 
Saarto et al reported the results of a trial of 299 women with node-positive breast 
cancer who were randomly assigned to receive clodronate 1600 mg/day or placebo for 
three years. All patients received adjuvant therapy; premenopausal women received 
CMF chemotherapy and postmenopausal women were treated with antiestrogens. 
After a follow-up of five years, there was no significant difference in the frequency of 
bone metastases between the clodronate and control arms. In contrast to the Diel 
study, however, the incidence of nonosseous metastases was significantly higher in 
the clodronate arm (43% v. 25%). Both DFS (56% v. 71%) and OS were significantly 
worse in the clodronate arm than in the controls (70% v 83%). Although more patients 
in the clodronate group had hormone-receptor negative tumors at baseline, the adverse 
effect of clodronate on DFS (but not on OS) remained significant in multivariate 
analyses after adjustment for prognostic factors like hormone receptor status, number 
of lymph nodes and tumor size (308). Quite recently, Saarto et al have updated their 
results after ten years of follow-up. The results remained stable: the incidence of 
skeletal metastases did not differ between the treatment groups, while the incidence of 
extraskeletal metastases was significantly higher in the clodronate group. Similarly, 
ten-year DFS remained significantly lower in the clodronate than in the control group 
(45% v. 58%), but this did not significantly compromise OS. The adverse effect of 
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 clodronate was especially seen in estrogen-receptor negative patients, where the 10-
year DFS was 25% in the clodronate group and 58% in the control group (309).  
 
In the double-blind trial by Powles et al, 1 069 women with node-negative or node-
positive breast cancer were randomly assigned to receive either clodronate 1600 
mg/day or placebo for a duration of two years. The categories of no adjuvant therapy, 
chemotherapy, tamoxifen, or both chemotherapy and tamoxifen were balanced 
between the arms. During the two years of clodronate use, bone metastases were 
significantly less frequent in the treatment group as compared to the placebo group 
(2.3% v. 5.2%). At five years of follow-up, the incidence of bone metastases was no 
longer significantly different between the clodronate and control arms (12% v. 15%).  
No difference in the frequency of nonosseous metastases was observed (21% v. 24%, 
respectively). OS was significantly improved in the clodronate arm (82% v. 76%) 
(310).  
 
Thus, two of the adjuvant clodronate trials yielded favorable results and one 
demonstrated an adverse impact. The three trials differ with regard to the patient 
characteristics and the study protocol. In the Diel study, all patients had bone marrow 
micrometastases.  In the study by Saarto only node-positive patients were included as 
compared to only 37% and 50% of node-positive patients in the Powles and Diel 
study, respectively. The duration of clodronate treatment was three years in the Saarto 
study and two years in the other two trials (305, 308, 310). 
 
In all three trials clodronate prevented or delayed the appearance of bone metastases; 
even in the study by Saarto et al, bone as the first site of relapse was less frequent in 
the clodronate than in the control group. The results of the influence of clodronate on 
nonosseous metastases, however, are controversial. Given that the three trials are 
inconsistent, it remains uncertain whether bisphosphonates are beneficial as adjuvant 
treatment. The largest adjuvant bisphosphonate study so far is ongoing (NSABP trial 
B34), with 2 400 early stage breast cancer patients randomly assigned to adjuvant 
clodronate or placebo, and will hopefully answer some questions raised by the former 
studies. Additionally, the North American Intergroup will conduct an adjuvant 
bisphosphonate trial (S0307) comparing oral clodronate to risedronate and zoledronic 
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 acid. At present, adjuvant bisphosphonates cannot be recommended for women about 
to undergo systemic adjuvant therapy outside clinical trials (248). 
 
7.4.2 Effect on bone mineral density 
 
Adjuvant therapy for breast cancer can be associated with decreased BMD that may 
lead to osteoporosis and skeletal morbidity. Current evidence from clinical trials 
indicates that bisphosphonates are effective in maintaining bone density in women 
receiving adjuvant therapy for breast cancer. 
 
Women who develop chemotherapy-induced ovarian failure undergo accelerated and 
highly significant bone mineral loss while those who continue to menstruate have 
only minimal changes in BMD (26, 195). Risedronate and clodronate have been 
evaluated in breast cancer patients with chemotherapy-induced early menopause. 
Intermittent oral risedronate for two years prevented effectively the bone loss 
observed in the placebo group (311). Another oral bisphosphonate, clodronate, 
significantly reduced bone loss in premenopausal patients who developed amenorrhea 
after adjuvant CMF chemotherapy (26). Similarly, oral clodronate for two years 
reduced the loss of BMD in patients who received adjuvant chemotherapy and/or 
tamoxifen (312).  
 
Ovarian ablation with LHRH analogs causes chemical castration, which in turn leads 
to a rapid decrease in BMD in premenopausal breast cancer patients (219). 
Intravenous bisphosphonate zoledronate maintained bone density in premenopausal 
breast cancer patients made functionally postmenopausal with LHRH agonist 
goserelin use (313).  
 
In postmenopausal patients with early breast cancer, aromatase inhibitors reduce 
BMD and increase the risk of osteoporosis (84-86, 216). Preliminary data suggests 
that the bone loss associated with adjuvant letrozole may be preventable with 
zoledronic acid given every six months (314). 
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 8. LONG-TERM EFFECTS OF ADJUVANT TREATMENTS ON LIPID 
METABOLISM 
 
8.1 Lipid metabolism and atherosclerosis 
 
High levels of total and low-density lipoprotein (LDL) cholesterol are well-
recognized risk factors for atherosclerotic disease, in particular coronary heart disease 
(CHD) (315). Small, dense and oxidized LDL particles are considered particularly 
atherogenic (316). Lipoprotein(a) (Lp(a)) consists of an LDL particle covalently 
attached to apolipoprotein(a). High plasma levels of Lp(a) have been positively 
associated with atherosclerosis, myocardial infarction and stroke (317). The 
atherogenity of Lp(a) is at least partly associated with an elevated concentration of 
LDL cholesterol (318). Plasma levels of high-density lipoprotein (HDL) cholesterol, 
on the other hand, are consistently inversely associated with CHD risk in 
observational studies (319, 320). The cardioprotective effects of HDL cholesterol 
have been attributed to its role in reverse cholesterol transport, its effects on 
endothelial cells, and its antioxidant activity (321, 322). The role of triglycerides in 
the development of CHD is less evident. A meta-analysis of 17 prospective 
population-based studies found hypertriglyceridemia to be an independent risk factor 
for cardiovascular disease (323). Nevertheless, it is possible that, rather than being 
actual atherogenic agents in themselves, elevated triglycerides merely serve as a 
marker for increases in triglyceride-rich remnant lipoproteins and that it is these latter 
particles that are involved in the development of atherosclerosis (316, 324). 
 
Atherosclerosis is a slowly progressing, pathological process involving the intima and 
media of large- and medium-sized arteries. The response-to-injury hypothesis behind 
the pathogenesis of atherosclerosis currently emphasizes endothelial dysfunction 
because of injury to the endothelial wall. Different forms of injury increase the 
adhesiveness and permeability of the endothelium and induce the endothelium to have 
procoagulant instead of anticoagulant properties (325). In addition to endothelial 
dysfunction, monocyte adhesion, lipid accumulation and oxidation, smooth muscle 
proliferation and extracellular matrix deposition contribute to the formation of 
atherosclerotic plaques (326). Concurrently with lipid accumulation, signs of 
inflammation occur in the artery wall (327). The atherosclerotic plaques do not 
usually interfere with arterial flow in the early stage of the disease. When thrombosis 
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 is superimposed on non-stenotic lesions, however, blood flow is impaired and may 
lead to ischaemia of target organs heart, brain or extremities.  
 
Endothelial injury may result from free radicals caused by elevated LDL cholesterol 
levels, smoking, hypertension, diabetes or hyperhomocystinemia (325). An infectious 
etiology has also been suggested as microorganisms like Chlamydia pneumoniae have 
been identified in atheromatous coronary artery lesions (328). Further, elevated levels 
of the inflammatory marker C-reactive protein (CRP) can indicate low-grade chronic 
inflammation and thus help to identify patients at risk for atherosclerotic 
complications (327).    
 
While the role of other factors in the development of atherosclerosis and CHD are 
being extensively studied, LDL cholesterol remains the primary target of therapy for 
the prevention and treatment of coronary heart disease (316). Reduction of total and 
LDL cholesterol is associated with numerous sequelae which attenuate atherogenesis, 
including improved endothelial function, reduced oxidative stress and reduced 
inflammation (329). Clinical trials of 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase inhibitors (statins) have confirmed that LDL cholesterol 
reduction significantly reduces cardiovascular morbidity and mortality in primary and 
secondary cardiovascular disease prevention (330, 331). A recent meta-analysis on the 
effectiveness of statin therapy reviewed 25 studies enrolling 69 511 individuals with 
CHD. According to this meta-analysis, statin therapy reduced CHD mortality by 23% 
and all-cause mortality by 16% as compared to placebo. The risk of nonfatal 
infarction was reduced by 25% with statins (332). 
 
8.2 Estrogen and lipid metabolism 
 
Estrogen decreases the serum levels of LDL cholesterol by inducing the expression of 
hepatic LDL receptors and thus enhancing the clearance of LDL cholesterol from 
plasma. Estrogens are thought to increase HDL cholesterol by reducing hepatic 
triglyceride lipase activity that catabolizes HDL (333). Estrogen has also been shown 
to lower Lp(a) levels (334). Menopause in turn causes changes in serum lipids that are 
explained by the deficiency of estrogens: serum total and LDL cholesterol and 
triglyceride levels increase and HDL cholesterol levels decrease (13-17). These 
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 changes in serum lipid profile are considered atherogenic and contribute to the 
increased risk of CHD in postmenopausal women. Consequently, the incidence of 
CHD in women increases after the menopause (335).  
 
Estrogen replacement therapy reduces plasma levels of LDL cholesterol and increases 
levels of HDL cholesterol, changes known to be associated with a reduced risk of 
cardiovascular disease (336). Estrogen has also been shown to inhibit oxidation of 
low-density lipoprotein, improve endothelial vascular function and reverse 
postmenopausal increases in fibrinogen and plasminogen-activator inhibitor type 1 - 
changes that should also reduce the risk of cardiovascular disease  (337). However, 
estrogen also has adverse physiological effects, including increasing the plasma levels 
of triglycerides, small, dense LDL particles, CRP and some thrombotic markers (338, 
339).  
 
Observational studies have suggested that postmenopausal hormone replacement 
therapy (HRT) reduces the risk of CHD (340). Recent randomized trials, however, 
have either provided no evidence of cardiac protection or even some evidence of harm 
when HRT has been given to women with CHD (336, 341). Moreover, the first 
randomized trial to directly study the effects of estrogen plus progestin therapy on 
CHD incidence in previously healthy postmenopausal women, was stopped early 
because it was found that the health risks associated with HRT exceeded the benefits. 
In this Women's Health Initiative (WHI) trial, HRT with estrogen plus progestin 
increased the risk of CHD among generally healthy postmenopausal women by 24% 
as compared to placebo (338). Though, as the criticism against the WHI trial states, 
many of the “healthy” women included actually had either CHD or several risk factors 
for CHD at randomization. HRT with estrogen only did not affect the risk of CHD 
(342). 
 
8.3 Adjuvant chemotherapy and serum lipids 
 
The effect of adjuvant chemotherapy on serum lipids has not been extensively studied. 
A few small studies on breast cancer patients at various stages of the disease have 
been published with conflicting findings (18, 343, 344). 
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 As explained earlier, adjuvant chemotherapy causes ovarian failure in a majority of 
premenopausal women with early breast cancer. The incidence of adjuvant 
chemotherapy induced amenorrhea varies depending on the drug combination used 
(191). The changes in serum lipids after adjuvant chemotherapy seem to correlate to 
changes in ovarian function: patients who preserve menstruation have stable lipid 
levels while those with chemotherapy-induced menopause develop possibly 
atherogenic changes in serum lipids. Total cholesterol, LDL and HDL cholesterol 
levels have been shown to increase in patients with chemotherapy-induced ovarian 
dysfunction (18), but no long-term data is available on this subject. 
 
8.4 Adjuvant endocrine therapy and serum lipids 
  
Tamoxifen has favorable and possibly antiatherogenic effects on lipid metabolism. 
Tamoxifen reduces the plasma concentrations of total and LDL cholesterol by 
downregulation of cholesterol synthesis (345). The effect of tamoxifen treatment on 
HDL cholesterol has been small (19-22, 346).  In contrast to the favorable effects of 
tamoxifen on total and LDL cholesterol, tamoxifen has been shown to increase the 
serum triglyceride concentrations (19, 21, 347) and contribute to the development of 
fatty liver (hepatic steatosis) (348). Further, tamoxifen has demonstrated effects on 
inflammatory markers that are consistent with reduced cardiovascular risk. 
Reductions in CRP and fibrinogen have been noted with tamoxifen use (349). 
 
In line with the findings of the recent trials on postmenopausal hormone replacement 
therapy and CHD risk, the favorable lipid effects of tamoxifen do not necessarily 
translate to reductions in cardiac risk. Few randomized trials suggested that adjuvant 
tamoxifen might have a cardioprotective effect in postmenopausal women (350-352). 
However, a large (n= 13 388) placebo-controlled randomized chemoprevention study 
failed to show any effects of tamoxifen on cardiovascular risk (206). 
 
The effects of toremifene on plasma lipids seem even more favorable than those of 
tamoxifen. Like tamoxifen, also toremifene lowers total and LDL cholesterol by 
downregulating cholesterol synthesis and reduces Lp(a) levels (345, 354, 355). In 
contrast to tamoxifen, however, HDL cholesterol levels have been shown to increase 
and triglyceride levels either steady or even decrease during toremifene use (21, 354). 
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 Randomized trials of raloxifene's use in postmenopausal women have consistently 
demonstrated a reduction in serum LDL cholesterol levels, while no apparent effect 
on HDL cholesterol or triglyceride levels has been noted (211, 356). Secondary 
analysis of data from the MORE trial showed a significant reduction in the risk of 
cardiovascular endpoints in a subset of women with increased risk for cardiovascular 
disease (357). A randomized, placebo-controlled trial of raloxifene for the prevention 
of coronary heart disease events is under way. 
 
The aromatase inhibitors anastrozole, letrozole and exemestane have shown 
somewhat different effects on serum lipid profile. In the metastatic setting, 
anastrozole did not show any major effects on lipids (358).   In a small adjuvant study 
on Japanese women anastrozole did not induce any significant changes in total and 
LDL cholesterol but led to a increase in HDL cholesterol and decrease in triglyceride 
levels (359). The largest adjuvant aromatase inhibitor study ATAC reported that the 
patients receiving anastrozole had higher cholesterol levels than those receiving 
tamoxifen (81). In few studies, letrozole had no effect on serum lipid profiles (83, 
360), while in one small study levels of both total and LDL cholesterol increased 
during letrozole administration (361). In contrast, exemestane has shown no adverse 
effects on cholesterol levels and seems even to decrease the serum triglycerides in 
patients with metastatic breast cancer (362). 
 
The effects of two SERMs (tamoxifen and toremifene) and two aromatase inhibitors 
(anastrozole and exemestane) on serum lipids were compared in an adjuvant study on 
180 postmenopausal women with early breast cancer. In line with previous studies, 
both tamoxifen and toremifene lowered significantly the levels of total and LDL 
cholesterol, but the effects on HDL cholesterol and triglycerides differed. Tamoxifen 
lowered and toremifene raised the levels of HDL cholesterol, while triglycerides 
increased during tamoxifen administration and decreased during toremifene treatment. 
The aromatase inhibitors anastrozole and exemestane induced modest decreases in 
total and LDL cholesterol. Anastrozole had no effect on serum HDL cholesterol or 
triglyceride levels, while exemestane somewhat lowered the levels of both (363). 
 
In conclusion, while all SERMs reduce the total and LDL cholesterol concentrations, 
the lipid profile seems most favorable with toremifene as it also reduces triglyceride 
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 levels and raises those of HDL cholesterol. The effects of aromatase inhibitors on 
serum lipids seem modest. Still, all the major adjuvant studies have suggested a 
somewhat increased, albeit not significant, risk of cardiovascular events during 
treatment with an aromatase inhibitor as compared to tamoxifen (86, 124, 121). 
 
The effects of adjuvant treatments on serum lipids are summarized in Table 4. 
 
Table 4. Effects of adjuvant treatments on serum lipids 
 Chemotherapy 
 
Tamoxifen Toremifene Anastrozole Letrozole Exemestane 
Total 
cholesterol 
 
         ↑↑* 
 
      ↓↓ 
 
        ↓↓ 
 
         −/↑ 
 
       −/↑ 
 
        ↓ 
LDL 
cholesterol 
 
         ↑↑* 
 
      ↓↓ 
 
        ↓↓ 
 
         −/↑ 
 
       −/↑ 
 
        ↓ 
HDL 
cholesterol 
 
         ↑↑* 
 
      −/↓ 
 
         ↑↑ 
 
         −/↑ 
 
       − 
 
        ↓ 
Triglycerides           −*       ↑↑           ↓          −/↓        −         ↓ 
↓ decrease (trend), ↓↓ decrease (significant), ↑ increase (trend), ↑↑ increase (significant), − no change, * 
in chemotherapy-induced amenorrhea  
 
52
 
 9. AIMS OF THE PRESENT STUDY 
 
This study in premenopausal patients with early breast cancer aimed to investigate: 
 
1. The long-term effects of chemotherapy-induced premature menopause and 
adjuvant peroral clodronate treatment on bone mineral density (I). 
 
2. The effect of short-term intravenous adjuvant clodronate treatment in the 
prevention of bone loss related to chemotherapy-induced premature 
menopause (II). 
 
3. The impact of adjuvant tamoxifen treatment on bone mineral density after 
adjuvant chemotherapy (III). 
 
4. The effect of adjuvant tamoxifen treatment on serum lipids after adjuvant 
chemotherapy (IV). 
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 10. PATIENTS AND METHODS (I-IV) 
 
10.1 Patients 
 
Two separate populations of premenopausal patients with early breast cancer were 
studied. The earlier population (named MACLO) comprised 148 node-positive 
patients treated with adjuvant chemotherapy and randomized to oral clodronate for 
three years or controls (I). The later population (named MACLOT) included 159 
patients with either node-positive disease or node-negative disease with other risk 
factors. After adjuvant chemotherapy, five-year tamoxifen was started to hormone 
receptor-positive patients (II-IV).  In addition, the first 48 patients were randomly 
allocated to receive intermittent intravenous clodronate treatment or no further 
therapy. The patients were treated at the Helsinki University Hospital, Department of 
Oncology. Informed consent was obtained from all participants. The Local Ethical 
Committee approved the studies. 
 
The patients included were ≤50 years of age. Premenopausal status at entry was 
defined as women with regular menstruation or last menstrual cycle within three 
months and serum follicle stimulating hormone (FSH) levels <30 IU/l (I) or as 
ongoing menstruation during the last six months (II-IV). The MACLO population 
included three hysterctomized women with premenopausal FSH levels (I), but 
hysterectomized subjects were excluded from the MACLOT population (II-IV). 
Patients with a Karnofsky performance index below 70%, other malignancies, peptic 
ulcer, serum creatinine above 150 umol/l, pregnancy, osteoporosis, medication 
affecting bone metabolism or untreated hypo- or hyperthyroidism were excluded.   
 
The patients had undergone surgery with axillary evacuation and total mastectomy or 
breast-conserving resection. Postoperative radiotherapy was given to those treated 
with breast conserving surgery and to those diagnosed with axillary lymph node 
metastases. The patients in the MACLO population were treated with six cycles of 
CMF chemotherapy (cyclophosphamide 600 mg/m², methotrexate 40 mg/m² and 5-
fluorouracil 600 mg/m²) intravenously on day one at three weeks intervals. In 
addition, the patients were randomized to receive or not to receive oral clodronate 
(Bonefos®, Leiras) 1600 mg daily for three years (I). Patients of the MACLOT 
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 population received either CMF or CEF (cyclophosphamide 600 mg/m², epirubicin 60 
mg/m²and 5-fluorouracil 600 mg/m²) chemotherapy and adjuvant five-year tamoxifen 
was started to those with hormone-receptor positive tumors after chemotherapy. In 
addition, 48 patients from the MACLOT population were randomly allocated to 
receive 1500 mg clodronate intravenously before each chemotherapy infusion or no 
further therapy. 
 
Patients who developed metastatic disease during follow-up were excluded from the 
analyses. Those lost for follow-up or having medication other than prescribed 
according to study protocol affecting bone (I-III) or lipid metabolism (IV) were also 
excluded. Patients having received intravenous clodronate (II) were excluded from the 
study examining the effect of tamoxifen on BMD (III) but were included in the study 
on the effects of tamoxifen on lipid metabolism (IV).  
 
10.2 Methods 
 
10.2.1 Clinical investigation and menopausal status 
 
At entry, all patients underwent clinical examination, liver ultrasound, chest x-ray and 
bone scintigraphy to rule out hematogenic metastases. Basic laboratory tests before 
randomization included a complete blood count and sedimentation rate, liver enzymes 
(transaminase, AFOS, 5-nucleotidase), serum creatinine, calcium and electrolytes. 
During the follow-up visits, the patients were clinically investigated and interviewed 
regarding menstrual status, medications and other diseases at one, two, three and five 
years (I) or at six months, one and three years thereafter (II-IV). Bone scintigraphy (I) 
and measurements of serum FSH, luteinizing hormone (LH) and estradiol were 
repeated before treatment and at one, two, three and five years (I) or before treatment 
and at three, six and 9 months and at one and three years (II-IV).  
 
The menstrual status of the patients was defined during each follow-up visit as part of 
the interview. Amenorrhea was defined as absent menstruation for at least six months.  
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 10.2.2 Dual energy X-ray absorptiometry (DXA) 
 
BMD (grams per square centimeter) was measured by DXA using a Hologic QDR- 
densitometer (Hologic, Inc., Waltham, MA). BMD was measured in the lumbar 
vertebrae (L1-4) and the femoral neck, femoral trochanter and Ward´s triangle, 
intertrochanteric and total femoral area in the right femoral area, both before initiation 
of chemotherapy, and at one, two, three and five years (I) or at six months, one and 
three years thereafter (II-III).  
 
10.2.3 Radioimmunoassays for bone markers PINP and ICTP 
 
For the 48 patients randomized to intermittent intravenous clodronate parallel to 
chemotherapy or to controls, the biochemical measurements (radioimmunoassays) of 
the bone turnover markers PINP and ICTP were performed at the beginning of 
chemotherapy and at three, six, 9 and 12 months thereafter (II). The serum samples 
were stored at –20º C. The reference interval of PINP for adult women is 19-84 ug/l 
and that of ICTP is 1.7-4.6 ug/l. The methods for the PINP and ICTP assays have 
been described elsewhere (179, 364). 
 
10.2.4 Assays of serum lipid levels 
 
Fasting serum levels of total, LDL and HDL cholesterol and triglycerides were 
measured before chemotherapy and at three, six, 9 and 12 months thereafter (IV). The 
serum cholesterol level was determined with an enzymatic colorimetric CHOD-PAP 
method and the triglyceride level with an enzymatic colorimetric GPO-PAP method 
(Roche Diagnostics). The concentration of HDL cholesterol was measured by an 
enzymatic HDL-C plus 2nd generation method (Roche Diagnostics). The equipment 
used to measure serum cholesterol, HDL-cholesterol and triglyceride levels was a 
Hitachi 917 or Modular analysator (Hitachi Ltd, Tokio, Japan). LDL cholesterol was 
calculated according to Friedewald equation (LDL-cholesterol = cholesterol - HDL-
cholesterol - Trigly / 2.2) (365). 
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 10.2.5 Statistical methods 
 
All statistical analyses were performed with the program SPSS for Macintosh. BMD 
values are presented as percentages of the baseline value (I-III). The repeated 
measurements ANOVA model was used to test the effect of the treatments 
(chemotherapy, clodronate and tamoxifen) and menstrual status on BMD. Other 
comparisons were performed using the Mann-Whitney test or Wilcoxon matched pair 
test. Ninety-five percent confidence intervals were calculated for the main outcome 
measures.  
 
Changes in the collagen metabolites were analyzed as the logarithmic transform of the 
PINP and ICTP levels divided by the baseline level. The logarithmic transformations 
were used because the collagen metabolites were non-normally distributed. The 
correlations between bone marker levels and the BMD were assessed using 
Spearman’s rank-order correlation coefficient (r) (II). 
 
The Wilcoxon matched pair test was used to compare lipid and hormonal changes 
within the treatment (tamoxifen/control) and menstrual groups. The repeated 
measurements ANOVA model was employed to test the effect tamoxifen treatment 
and menstrual status on serum lipid levels. The correlations between the changes in 
serum lipids and weight were assessed by Spearman´s rank-order correlation 
coefficient. Other comparisons were performed using the Mann-Whitney test (IV). 
 
To address the statistical problem of multiple comparisons, the significance level was 
set at 0.01 in all studies. The information on patients and methods is summarized in 
Table 5. 
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 Table 5. Patients and methods in Studies I (MACLO) and II-IV (MACLOT) 
  
MACLO (n=148)
 
MACLOT (n=159)
  
Study I 
 
Study II 
 
Study III 
 
Study IV 
n  73  45 111 146 
Follow-up 5 years 1 year 3 years 1 year 
Menstrual status: * 
Menstruating 
 
26% 
 
31% 
 
29% 
 
46% 
Amenorrheic 74%  69% 71% 53% 
Investigation p.o. CLO → BMD i.v. CLO →BMD TAM →BMD TAM →lipids 
Methods DXA DXA, 
bone markers 
DXA serum lipids 
CLO = clodronate, i.v. = intravenous , n= number of patients, p.o. = peroral, TAM = tamoxifen, * = at 
follow-up. All patients were treated with adjuvant chemotherapy. 
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 11. RESULTS 
 
11.1 Chemotherapy, clodronate and tamoxifen treatment: Effects on bone 
mineral density (I, II, III) 
 
11.1.1 Effect of chemotherapy on bone mineral density (I, II, III) 
 
Adjuvant chemotherapy caused ovarian dysfunction and amenorrhea in the majority 
of the patients. In the MACLOT population, 69% and 71% of the patients had 
developed amenorrhea during one and three years of follow-up, respectively (II, III). 
In the MACLO population with the longest follow-up, 74% of the patients were 
permanently amenorrheic five years after chemotherapy (I). The risk of amenorrhea 
was age-dependent: the mean age of the patients at the start of the chemotherapy was 
46 and 47 years for those who developed amenorrhea and 37 and 39 years for those 
who continued to menstruate (III and I, respectively). 
 
Changes in BMD correlated significantly with menstrual function after adjuvant 
chemotherapy. At three years of follow-up, patients with chemotherapy-induced 
amenorrhea had lost -9.5% (95% confidence interval of change (95%CI) -12.4% to -
6.5%) of their baseline lumbar spine BMD, while those who continued to menstruate 
had a modest gain of +0.6% (95%CI –1.8% to +3.0%) For the femoral neck, the 
corresponding BMD losses were -4.9% (95%CI –8.6% to –1.2%) and –1.4% (95%CI 
–4.0% to +1.2%), respectively (III).  At five years of follow-up, a similar significant 
correlation between BMD changes and menstrual function was observed. Five years 
after adjuvant chemotherapy, amenorrheic patients had lost –10.4% (95%CI –12.0% 
to –8.9%) of their baseline lumbar spine BMD values while those with ongoing 
menstruation had only minimal loss of –1.3% (95%CI –3.5% to +0.9%) (p=0.0001). 
The corresponding changes at the femoral neck were –5.8% (95%CI –7.5% to –4.0%) 
and –0.3% (95%CI –3.3 to + 2.7%) (p=0.001). The rate of bone loss in amenorrheic 
patients decreased from the first few years of rapid bone loss to the fifth year of 
follow-up (I). 
 
Thus, a marked bone loss occurred in women who developed chemotherapy-induced 
ovarian failure and early menopause, while those who continued to menstruate despite 
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 the chemotherapy preserved their baseline BMD levels. The bone loss was most 
marked during the first few years after chemotherapy. 
 
11.1.2 Effect of clodronate on bone mineral density (I, II) 
 
11.1.2.1 Effect of peroral long-term clodronate on bone mineral density (I) 
 
In the MACLO population (n=148), the patients were randomized to oral clodronate 
for three years or to controls in addition to adjuvant CMF chemotherapy. 73 disease-
free patients were included in the five-year follow-up study on peroral clodronate and 
BMD. After three years of clodronate treatment, the bone loss in the lumbar spine was 
significantly less than in the controls, –3.0% and –7.4%, respectively (p=0.003), while 
no significant differences between the treatment groups were found in the femoral 
neck BMD. At five years, two years after termination of the clodronate treatment, the 
bone loss in the lumbar spine was still significantly less in clodronate-treated patients 
compared to controls, -5.8% and –9.7%, respectively (p=0.008). Following 
discontinuation of the treatment, both the patients previously treated with clodronate 
and the control patients lost bone mass at similar rates. Thus, no acceleration of bone 
loss after treatment termination was observed (Figure 1). 
 
 
 
Figure 1. Percentual changes and 95%CIs in lumbar spine and femoral neck BMD in clodronate 
(dotted line) and control (bold line) groups 
 
At five years, the patients were further divided into those who preserved menstruation 
and into those who became amenorrheic during follow-up. The beneficial effect of 
clodronate on BMD was evident in both menstruating and amenorrheic women. The 
small bone loss of the menstruating women was totally prevented by clodronate. 
However, the rapid bone loss seen among patients who experienced chemotherapy-
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 induced ovarian failure was reduced 29-40% but not prevented by clodronate (Figure 
2).  
 
 
 
Figure 2. Percentual changes and 95%CIs in lumbar spine and femoral neck BMD according to 
menstrual status in clodronate (dotted line) and control (bold line) groups  
 
 
11.1.2.2 Effect of intravenous short-term clodronate on bone mineral density (II) 
 
In the MACLOT population (n=159), the first 48 patients were randomized to 
intravenous clodronate parallel to adjuvant CMF or CEF chemotherapy. 45 disease-
free patients were included in the study on short-term intravenous clodronate on 
BMD. Chemotherapy caused amenorrhea in 69% of the patients during one year of 
follow-up. The intermittent, short-term intravenous clodronate did not prevent the 
bone loss associated with chemotherapy-induced ovarian failure in this small study. 
At six months, the change in lumbar spine BMD was -0.5% in the clodronate group 
and -1.4% in the control group (p=0.22), and, in the femoral neck -0.4% and -1.9%, 
respectively (p=0.37). The bone loss in the lumbar spine at 12 months was -3.9% in 
the clodronate group and -3.6% in the control group (p=0.62), and, in the femoral 
neck -1.4% and -2.9% (p=0.43), respectively (Figure 3). While the effect of 
clodronate treatment on BMD change at 12 months was not significant, a highly 
significant effect of menopausal status (amenorrhea vs. irregular or regular 
menstruation) was found in the lumbar spine (p=0.008). In the femoral neck, the 
effect of menopausal status on BMD was not statistically significant (p=0.31). 
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Figure 3. Percentual changes and 95%CIs in lumbar spine and femoral neck BMD in the 
clodronate (dotted line) and control (bold line) groups 
 
In conclusion, oral clodronate treatment for three years significantly reduced bone 
loss in the lumbar spine. A four-monthly intermittent intravenous clodronate 
treatment, on the other hand, did not prevent the bone loss associated with 
chemotherapy-induced ovarian failure. 
 
11.1.2.3 Effect of short-term intravenous clodronate on bone markers PINP and 
ICTP (II) 
 
Although intravenous intermittent four-monthly clodronate could not prevent the 
rapid bone loss associated with chemotherapy-induced early menopause, the serum 
levels of bone turnover marker PINP decreased significantly during clodronate 
treatment. The median PINP levels at three and six months were significantly lower in 
the clodronate group than in the control group: at three months 17.5 ug/l (range 11.6 - 
59.10 ug/l) and 29.3 ug/l (range 19.8 - 54.0 ug/l), and at six months 22.6 ug/l (range 
15.7 - 55.8 ug/l) and 44.0 ug/l (range 12.5 - 91.9 ug/l). Thereafter, at 9 and 12 months, 
no significant difference between the treatment groups was found. The PINP levels 
decreased in the patients treated with clodronate while the PINP levels rose in the 
control group at six months. The mean change in PINP values from randomization to 
six months was -28.7% and +21.8% (p=0.0003), and from randomization to 12 
months +44.9% and +37.7% (p=0.34) in clodronate and control groups, respectively 
(Figure 4). 
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Figure 4. Percentual changes and 95%CIs in PINP values in clodronate (dotted line) and control 
(bold line) groups 
 
The serum levels of the other bone turnover marker ICTP did not differ between the 
clodronate and control groups. 
 
In conclusion, serum levels of the bone marker PINP decreased significantly during 
clodronate treatment reflecting reduced bone turnover. 
 
11.1.3 Effect of tamoxifen on bone mineral density (III) 
 
In the MACLOT population (n=159), adjuvant five-year tamoxifen after CMF or CEF 
chemotherapy was started to those patients with hormone-receptor-positive tumors 
(tamoxifen group) while patients with hormone-receptor-negative tumors received no 
further treatment (control group). 111 disease-free patients were included in the study 
of tamoxifen and BMD, 88 in the tamoxifen group and 23 in the control group. Again, 
chemotherapy caused amenorrhea in the majority (71%) of the patients.  
 
Tamoxifen treatment caused a significant bone loss in lumbar spine BMD in 
premenopausal patients who continued to menstruate three years after adjuvant 
chemotherapy. At three years of follow-up, the mean bone loss at lumbar spine was -
4.6% in the tamoxifen group while a modest gain of +0.6% was noted in the control 
group (Figure 5). At the femoral neck, tamoxifen-treated women lost –1.8% and 
women in the control group –1.4% of their baseline BMD values during the three-year 
observation period. 
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 Tamoxifen treatment reduced bone loss in patients with chemotherapy-induced 
amenorrhea. At three years of follow-up, women on tamoxifen had lost –6.8% of their 
baseline lumbar spine BMD while those without tamoxifen had lost –9.5% (Figure 5). 
At the femoral neck, tamoxifen-treated women lost –3.6% and those without 
tamoxifen  –4.9% of their baseline values.  
 
 
Figure 5. Percentual changes in lumbar spine BMD according to tamoxifen use and menstrual 
status 
 
The interaction between tamoxifen therapy and menstrual status on lumbar spine 
BMD changes seen during the three-year follow-up was highly significant 
(p<0.0001). A similar trend towards an interaction was noted between tamoxifen 
therapy and menstrual status on BMD changes at the femoral neck (p=0.075). 
 
In conclusion, tamoxifen had opposite effects on BMD depending on menstrual status. 
Tamoxifen caused bone loss in patients who continued to menstruate after adjuvant 
chemotherapy. Contrarily, tamoxifen decreased bone loss in those women who 
developed chemotherapy-induced amenorrhea. 
 
11.2 Chemotherapy and tamoxifen treatment: Effects on serum lipids (IV) 
 
11.2.1 Effect of chemotherapy on serum lipids (IV) 
 
In the MACLOT population (n=159), all patients received adjuvant CMF or CEF 
chemotherapy. 146 disease-free patients were included in the study on chemotherapy, 
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 tamoxifen and serum lipids. During one year of follow-up, 53% of the patients had 
developed amenorrhea, 32% had irregular menstruation and only 14% menstruated 
regularly. The mean age of the patients at the start of the chemotherapy was 47 years 
for those who developed amenorrhea, 41 years for those with irregular menstruation 
and 36 years for those who still menstruated regularly, respectively. The gonadotropin 
FSH and LH changes during the chemotherapy period correlated with the changes 
observed in the menstrual cycle.  
 
Changes in total and LDL cholesterol during chemotherapy (0-6 months) correlated 
significantly with menstrual function. In patients who developed amenorrhea, the total 
cholesterol increased by +9.5% and the LDL cholesterol by +16.6% (p<0.00001 and 
p<0.00001, respectively). The LDL/HDL ratio increased by +21.7% (p<0.00001) and 
the total cholesterol/HDL ratio by +13.3% (p<0.00001). The total cholesterol 
increased by +7.3% and LDL cholesterol by +11.8% in patients with irregular 
menstruation (p=0.003 and p=0.017, respectively). The LDL/HDL ratio increased by 
+14.7% (p=0.02) and the cholesterol/HDL ratio +9.4% (p=0.005). In patients who 
still menstruated regularly, the total cholesterol increased only +2.4% and the LDL 
cholesterol +3.0% (p=0.52 and p=0.57, respectively). Accordingly, LDL/HDL 
cholesterol and cholesterol/HDL cholesterol ratios remained unchanged.  
 
The differences in the changes of serum total and LDL cholesterol were insignificant 
between patients with amenorrhea and irregular menstruation (p=0.61 and p=0.22, 
respectively) but the differences in the changes of serum total and LDL cholesterol 
between patients with regular menses and irregular or absent menstruation 
(amenorrhea) were more marked (p= 0.04 and p=0.008). Similarly, the differences in 
the changes of LDL/HDL ratios and total cholesterol/HDL ratios were insignificant 
between patients with amenorrhea and irregular menstruation (p=0.50 and p=0.84), 
but the differences in the changes of LDL/HDL ratios were significant (p=0.006) and 
of total cholesterol/HDL ratios nearly significant (p=0.02) between patients with 
regular menses and irregular or absent menstruation (amenorrhea). Serum triglyceride 
levels increased and HDL cholesterol levels slightly decreased regardless of menstrual 
function and the differences between the groups were statistically insignificant. 
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 In conclusion, changes in total and LDL cholesterol during the chemotherapy 
correlated significantly with menstrual function. Only those patients who developed 
signs of ovarian failure had marked elevations in serum total and LDL cholesterol, 
while no significant changes occurred in those who menstruated regularly. 
 
11.2.2 Effect of tamoxifen on serum lipids (IV) 
 
Six months after the beginning of adjuvant chemotherapy, tamoxifen was started and 
continued for five years to those 112 patients with hormone-receptor-positive tumors 
(tamoxifen group) while the 34 patients with hormone-receptor-negative tumors 
received no further treatment (control group). The serum lipid levels were monitored 
in both groups during chemotherapy (0-6 months) and during the first six months 
thereafter (6-12 months).  
 
The total and LDL cholesterol and triglyceride levels increased during chemotherapy 
in all patients. However, during the first six months of tamoxifen treatment the total 
and LDL cholesterol decreased even below the pre-chemotherapy levels. In the 
control group, no significant decrease in the cholesterol levels was seen during the 
same six months of follow-up. The serum triglyceride remained at an increased level 
in both tamoxifen and control groups. 
 
Chemotherapy caused an increase of +6.5% and +12.2% in total cholesterol 
(tamoxifen and control groups, respectively), which was reversed during the 
following six months in patients on tamoxifen but not in control patients. The total 
cholesterol decreased –9.7% from the post-chemotherapy levels during the first six 
months of tamoxifen treatment but only –1.6% in the control group (p=0.001). 
Similarly, chemotherapy increased the LDL cholesterol levels (+11.5% and +18.0% 
in tamoxifen and control groups, respectively). During the first six months of 
tamoxifen the LDL cholesterol levels decreased by -16.7% while a decrease of only –
1.5% was noted in control patients (p<0.0001) (Figure 6). The changes in HDL 
cholesterol levels were minimal during chemotherapy and tamoxifen treatment had no 
significant effect on HDL cholesterol. The LDL/HDL cholesterol ratio increased in all 
patients during chemotherapy, but thereafter, a significant decrease was seen only in 
patients treated with tamoxifen (Table 6). 
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 Notably already after three months of tamoxifen therapy both total and LDL 
cholesterol levels had decreased even below the baseline levels measured before the 
chemotherapy: total cholesterol had decreased -4.6% and LDL cholesterol -8.3% 
below the baseline levels (p<0.0001 and p<0.0001, respectively). 
 
Table 6. The effect of tamoxifen (6-12 months) after chemotherapy (0-6 months) 
on lipid levels.  
      Tamoxifen  
0-6 months 
group 
6-12 months 
          Control  
0-6months 
group 
6-12 months 
Total cholesterol +6.5% -9.7%* +12.2% -1.6%* 
LDL +11.5% -16.7%** +18.0% -1.5%** 
HDL -2.0% +0.6% +1.2% +0.4% 
Triglyceride +22.3% +8.8% +32.8% +0.1% 
LDL/HDL +16.8% -15.0%* +18.9% +0.5%* 
Total cholesterol/HDL +10.5% -8.4% +12.0% -0.6% 
Significance of the difference between tamoxifen and control groups: * p<0.01, ** p<0.001 
 
 
 
 
 
Figure 6. Percentual changes (and 95%CIs) from pre-chemotherapy levels in serum LDL 
cholesterol in tamoxifen (bold line) and control (dotted line) groups 
 
In conclusion, adjuvant tamoxifen therapy reversed the adverse effects of 
chemotherapy on total and LDL cholesterol and lowered their serum levels even 
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 below the baseline. The serum HDL cholesterol levels, however, remained unchanged 
after chemotherapy followed by tamoxifen. 
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 12. DISCUSSION 
 
12.1 Adjuvant chemotherapy and bone mineral density 
 
During our follow-up period of five years, 74% of the premenopausal patients treated 
with adjuvant chemotherapy developed ovarian failure and amenorrhea. The risk of 
amenorrhea was age-dependent: the mean age of the patients at the start of the 
chemotherapy was 47 years for those who developed amenorrhea and 39 years for 
those who continued to menstruate (I). This is in line with prior findings that women 
most prone to develop ovarian failure and early menopause after chemotherapy are 
those 40 years of age or older (11, 193, 194). 
 
In the current study, marked bone loss occurred only in women who developed 
chemotherapy-induced ovarian failure and early menopause, while those who 
continued to menstruate preserved their BMD levels. Five years after adjuvant 
chemotherapy, the bone loss among amenorrheic patients was as high as –10.4% in 
the lumbar spine while menstruating patients had only minor BMD changes (I). The 
association between menstrual function and the BMD changes is in accordance with 
previous studies (26, 195).  
 
The rate of bone loss was greatest during the first few years after chemotherapy-
induced menopause and decreased thereafter. While the rate of bone loss observed 
after natural menopause is slower (366), the rapid bone-losing phase after 
chemotherapy resembles that seen after surgical oophorectomy and probably reflects 
the severe estrogen deficiency of iathrogenic menopause. In two earlier studies on the 
subject, the lumbar spine bone loss has averaged -7% during the first year after 
chemotherapy-induced ovarian failure (26, 195). In the current studies, the first annual 
bone loss at lumbar spine was slightly less (-4% to –6%). 
 
Chemotherapy-induced ovarian failure caused rapid and highly significant bone loss 
especially in the spine. The spine consists mainly of cancellous bone where bone 
turnover is fast and estrogen deficiency causes rapid bone loss. In the current study, 
bone loss at the femoral neck was less than that seen in the lumbar spine. This 
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 probably reflects the slower bone turnover of cortical bone tissue found at the femoral 
neck (367). 
 
The results of the current and earlier studies imply that women who develop 
chemotherapy-induced ovarian failure undergo significant bone mineral loss most 
pronounced in the lumbar spine. Thus, long-term breast cancer survivors may be at a 
higher than average risk for osteoporosis. Women with breast cancer and 
chemotherapy-induced early menopause should probably have their BMD monitored. 
Measures such as adequate calcium and D vitamin intake, regular weight-bearing 
exercice and avoidance of cigarette smoking should be encouraged. If osteoporosis 
develops, bisphosphonates may seem the most appropriate treatment for women with 
a history of breast cancer. 
 
12.2 Effect of clodronate on bone loss induced by adjuvant chemotherapy  
 
Oral clodronate for three years significantly reduced bone loss in the lumbar spine. As 
shown for the first time, still two years after termination of the clodronate treatment, 
the bone loss in the lumbar spine was significantly less in clodronate-treated patients 
compared to controls: the bone loss observed in the lumbar spine was –5.8% for 
patients on clodronate and -9.7% for controls, respectively (I). The bone loss was not 
accelerated after termination of the clodronate treatment. As most of the patients in 
both clodronate and control groups experienced early chemotherapy-induced 
menopause, clodronate could not prevent the rapid bone loss although diminished it. 
The effect of clodronate at the femoral neck was less marked than in the lumbar spine. 
This is probably related to the fact that bone turnover is faster in the spine than at the 
femoral neck (367). 
 
While long-term oral clodronate offered significant protection against bone loss, 
intermittent, intravenous short-term clodronate did not seem to prevent clinically 
significantly the bone loss related to chemotherapy-induced ovarian failure. However, 
a significant reduction of a biochemical bone turnover marker (PINP) was seen during 
the therapy (II). This suggests that even though the short-term intermittent intravenous 
clodronate treatment did reduce the bone turnover rate, the duration of the treatment 
(around four months) was insufficient to lead to long lasting clinically significant 
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 reduction of bone loss. The number of patients included in the study on intravenous 
clodronate, however, is small and the study may well be underpowered to detect a 
significant difference between the clodronate and control groups even if there is one.  
 
In our study on intermittent intravenous clodronate, there was a small difference in 
BMD favouring clodronate during the short treatment period but this was not 
statistically significant. This may be due to low statistical power or insufficient 
duration of treatment. It has been suggested that bisphosphonates need to be given for 
at least six months before an effect on skeletal morbidity is seen (150). 
Bisphosphonates are ingested by osteoclasts, which subsequently die, removing the 
drug from the site of active bone resorption. To cover the rapid bone loss seen after 
chemotherapy-induced ovarian failure, the bone should probably be loaded with 
bisphosphonates under longer periods than a few months.  
 
The optimal dose or route of clodronate administration for the treatment of 
osteoporosis is not yet established. Oral doses of 400-800 mg/day given cyclically or 
continuously have been successfully used in several large studies (29, 239, 240, 368). 
When comparing the dosing of peroral and intravenous routes, it should be noted that 
the bioavailability of clodronate is about 2% of the oral dose while around 20-30% of 
the intravenously administered dose remains in the bone (369). According to this, the 
intravenous dosage of 1500 mg every three weeks used in our study should compare 
with an oral dosing of 800 mg/day.  
 
A spectrum of different dosing regimens has been used in studies available on 
intermittent intravenous clodronate. In women with early postmenopausal bone loss, 
cyclical 200 mg clodronate given intravenously every month for two years was found 
to prevent bone loss (31). A long-term cyclical clodronate therapy with 200 mg 
infusion every three weeks for six years increased BMD significantly and reduced the 
incidence of vertebral fractures in women with postmenopausal osteoporosis (32). In a 
small study with patients on long-term parenteral nutrition and osteopenia, 1500 mg 
clodronate given intravenously every three months for one year significantly inhibited 
bone resorption as assessed by changes in biochemical markers of bone turnover. 
However, like in our study cyclic intravenous clodronate therapy failed to increase 
spinal BMD (370). 
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 Continuous peroral clodronate 400 mg/day has been compared with intermittent 
intravenous clodronate administered either as an 18-hour infusion of 1800 mg or by 
separate infusions of 300 mg over six consecutive days every 6 months in 
postmenopausal women with osteopenia. After two years of treatment, continuous 
peroral clodronate was found to be significantly more effective than the intermittent 
intravenous remedies (368). 
 
Current evidence indicates that bisphosphonates are effective in maintaining bone 
density in women receiving adjuvant therapy for breast cancer (26, 195, 311, 312). 
Both risedronate and clodronate have been shown to reduce bone loss in patients with 
chemotherapy-induced early menopause. Intermittent oral risedronate for two years 
prevented effectively the bone loss observed in the placebo group (311) and peroral 
clodronate for two years reduced the loss of BMD in patients who received adjuvant 
chemotherapy and/or tamoxifen (312). A significant bone loss was noted in 
premenopausal breast cancer patients treated with goserelin plus tamoxifen or 
goserelin plus anastrozole. When the same combined endocrine treatment was given 
with intravenous zoledronate every six months, no treatment-induced bone loss was 
seen (313). 
 
In conclusion, 1600 mg/day of peroral clodronate for three years significantly reduced 
bone loss in chemotherapy-induced early menopause. On the other hand, 1500 mg of 
clodronate given intravenously every three weeks for four months did not 
significantly reduce bone loss in breast cancer patients treated with adjuvant 
chemotherapy. This may be due to insufficient duration of the clodronate treatment. 
Bisphosphonate treatment, if given to prevent chemotherapy-induced bone loss, 
should probably cover the one to two years of most rapid bone turnover. The efficacy 
of different bisphosphonates has not been compared in this respect. So far, adjuvant 
bisphosphonate treatment is not standard practice outside clinical trials. 
 
12.3 Effect of intravenous clodronate on bone markers PINP and ICTP 
 
Serum levels of the bone formation marker PINP decreased significantly during 
clodronate treatment reflecting reduced bone turnover (II). PINP is a marker of bone 
formation intended to reflect the synthesis of type I collagen (179). While menopause 
72
 
 (181, 182) and osteoporosis (183) increase PINP levels, effective treatment of bone 
loss and osteoporosis decreases its serum concentrations (182, 185). PINP may be 
used in clinical practice among other bone turnover markers to help to identify bone 
loss and to monitor response to antiresorptive treatment such as bisphosphonate 
therapy.  
 
The serum ICTP levels did not change during clodronate treatment (II). ICTP is a 
degradation product of mature type I collagen and its serum concentration reflects 
type I collagen breakdown (186). ICTP has been reported to increase in such 
pathological conditions as bone metastases and rheumatoid arthritis (187). However, 
ICTP is rather insensitive to detect changes in bone turnover induced by osteoporosis 
or antiresorptive treatment (182, 188, 189). As shown recently, ICTP probably reflects 
the MMP-mediated bone resorption as seen with osteolytic bone metastases, but not 
the cathepsin K-mediated osteoclastic bone resorption of osteoporosis (371). ICTP 
does not seem useful in monitoring response to bisphosphonate treatment. 
 
12.4 Effect of tamoxifen after adjuvant chemotherapy on bone mineral density 
 
In the current study tamoxifen treatment after adjuvant chemotherapy had opposite 
effects on BMD depending on menstrual status. Tamoxifen treatment caused 
significant bone loss in patients who continued to menstruate after chemotherapy. At 
three years of follow-up, menstruating patients on tamoxifen had lost –4.6% of their 
baseline BMD values while a modest gain of +0.6% was noted in the control group. 
In contrast, tamoxifen reduced bone loss in patients who developed chemotherapy-
induced early menopause. In amenorrheic patients the lumbar spine BMD values 
decreased –6.84% in tamoxifen-users and –9.46% in the controls, respectively (III). 
 
The effects of tamoxifen on BMD are well established in postmenopausal patients. In 
this group of patients, tamoxifen significantly decreases the loss of BMD in the 
lumbar spine and to a somewhat lesser degree at the femoral neck (34-38, 200-205). 
While tamoxifen prevents bone loss in postmenopausal women, the opposite has been 
suggested for premenopausal women. In a placebo-controlled tamoxifen 
chemoprevention study, both lumbar spine and femoral neck BMD decreased 
progressively in tamoxifen users who remained premenopausal throughout the 
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 observation period (38). Similar findings were observed in the ZIPP trial comparing 
different endocrine approaches in early breast cancer, where a significant decline in 
total-body bone density was seen in premenopausal patients on tamoxifen (219). In 
our study, no bone loss occurred in women who continued to menstruate after 
chemotherapy and who were not given tamoxifen, whereas a significant bone loss was 
observed in menstruating patients given chemoendocrine therapy with tamoxifen. 
These findings are in accordance with results of the tamoxifen prevention trial and the 
ZIPP trial, which also reported bone loss in premenopausal women receiving 
tamoxifen (38, 219).  
 
Why do the effects of tamoxifen on BMD differ in pre- and postmenopausal patients? 
Tamoxifen is a SERM with estrogen antagonist or agonist effects dependent on the 
surrounding physiologic conditions and target tissue. Menopausal status modulates 
the effect of SERMs. Tamoxifen seems more estrogen antagonist than agonist in 
premenopausal women while the estrogen agonist properties prevail in 
postmenopausal women (90). In the presence of premenopausal levels of estrogen, 
tamoxifen seems to act as an estrogen-antagonist and cause bone loss. This has been 
suggested also in preclinical studies, where tamoxifen reduced bone mass in rats with 
intact ovaries (372, 373).  
 
In patients with chemotherapy-induced amenorrhea tamoxifen reduced bone loss but 
it did not totally prevent the bone loss. As stated before, bone loss in patients who 
develop amenorrhea after chemotherapy is extremely rapid and comparable to that 
seen after surgical oophorectomy (24, 26, 195). Even though tamoxifen is effective in 
preventing bone loss in the later postmenopause, it cannot counteract the sudden and 
rapid bone turnover seen during chemotherapy-induced perimenopausal transition 
period. 
 
To conclude, those patients with early breast cancer who continue to menstruate 
despite chemotherapy and are given adjuvant tamoxifen, seem to be at an increased 
risk of bone loss as compared to those still menstruating but not on tamoxifen. 
However, the bone loss is even more marked in patients who develop chemotherapy-
induced menopause. In these women, tamoxifen offers some protection against bone 
loss. Probably most long-term survivors of breast cancer who have received adjuvant 
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 therapy are at increased risk of osteoporosis and bone health intervention should be 
considered as part of their follow-up.  
 
12.5 Adjuvant chemotherapy and serum lipids 
 
We noted that changes in total and LDL cholesterol during the chemotherapy 
correlated significantly with menstrual function. Only those patients who developed 
either amenorrhea or irregular menstruation had marked elevations in serum total and 
LDL cholesterol, while no significant changes occured in those who continued to 
menstruate. Serum triglyceride levels increased during chemotherapy regardless of 
menstrual function while no significant changes in HDL cholesterol were noted (IV). 
 
A few small studies have looked at the effect of chemotherapy on lipid levels with 
somewhat inconsistent findings (18, 343, 344). In an earlier study on the subject, 
however, the serum levels of total and LDL cholesterol but also of HDL cholesterol 
have been shown to increase in patients with chemotherapy-induced ovarian 
dysfunction (18).  
 
In a premenopausal woman, circulating estrogens decrease the serum levels of LDL 
cholesterol (and thereby also total cholesterol) by enhancing the clearance of LDL 
cholesterol from plasma and increase HDL cholesterol levels by reducing hepatic 
lipase activity that degrades HDL (333). Natural menopause in turn causes changes in 
serum lipids that are explained by the deficiency of estrogens: serum LDL and total 
cholesterol levels increase and HDL cholesterol levels decrease. The triglyceride 
levels also tend to rise during menopause (13-17).  
 
Most patients in the current study developed either amenorrhea or irregular 
menstruation during the first year post-chemotherapy reflecting estrogen deficiency 
(IV). Thus, the increase in LDL and total cholesterol and triglycerides noted 
resembles the changes seen during natural menopause. Although changes in HDL 
cholesterol were negligible in the current study, the other changes seen in serum lipid 
profile are considered atherogenic. Consequently, those breast cancer patients who 
experience early menopause with premature adverse lipid effects may be at an 
increased risk of coronary heart disease (CHD).  
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 12.6 Effect of tamoxifen after adjuvant chemotherapy on serum lipids  
 
The total and LDL cholesterol and triglyceride levels increased during chemotherapy. 
However, during the first six months of tamoxifen treatment the total and LDL 
cholesterol decreased even below the pre-chemotherapy levels. In the control group, 
no significant decrease in the cholesterol levels was seen during the same six months 
of follow-up. The serum triglyceride remained at an increased level both in patients 
treated with tamoxifen and the controls. Tamoxifen treatment had no significant 
effects on HDL cholesterol.  
 
High levels of total and LDL cholesterol are well-recognized risk factors for 
atherosclerotic disease, in particular CHD (315). Also, hypertriglyceridemia may be 
an independent risk factor for cardiovascular disease (323). Plasma levels of HDL 
cholesterol, on the other hand, are inversely associated with CHD risk in 
observational studies (319). Tamoxifen has favorable and possibly antiatherogenic 
effects on lipid metabolism as it reduces the plasma concentrations of total and LDL 
cholesterol in postmenopausal patients (345). While the levels of total and LDL 
cholesterol have uniformly decreased in tamoxifen-treated women, the effect of 
tamoxifen treatment on HDL cholesterol has been minimal. However, tamoxifen may 
increase the serum triglyceride concentrations (347). 
 
In the present study, adjuvant tamoxifen therapy reversed the adverse effects of 
chemotherapy on total and LDL cholesterol. Tamoxifen therapy had no effect on HDL 
cholesterol. Triglyceride levels increased during adjuvant chemotherapy and remained 
high both in patients on tamoxifen and those with no further therapy. The possible 
clinical implications of these findings still need to be studied as many factors other 
than serum cholesterol levels affect the risk of cardiovascular disease. The effects of 
menopause, estrogen, chemotherapy and tamoxifen (including findings of the present 
study) on serum lipids are summarized in Table 7. 
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 Table 7. Effects of estrogen, menopause, chemotherapy and tamoxifen on serum 
lipids  
 Estrogen Menopause Tamoxifen Chemotherapy 
and menopause 
Tamoxifen after 
chemotherapy 
Total 
cholesterol 
     ↓       ↑       ↓           ↑           ↓     
LDL cholesterol      ↓       ↑       ↓           ↑           ↓ 
HDL 
cholesterol 
     ↑       ↓       −           ↑/−           − 
Triglycerides      ↑       ↑       ↑/−           ↑/−           ↑ 
↓ decrease, ↑ increase, − no change 
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 13. CONCLUSIONS 
 
 
1. Marked bone loss occurred in premenopausal women who developed 
chemotherapy-induced ovarian failure and early menopause, while those who 
continued to menstruate preserved their BMD levels. Oral clodronate for three 
years significantly reduced bone loss associated with ovarian failure. The 
positive effect of clodronate on BMD was still evident two years after 
termination of the treatment. 
 
2. Intermittent intravenous clodronate treatment for four months did not prevent 
the rapid bone loss associated with chemotherapy-induced ovarian failure. 
However, serum levels of the bone marker PINP decreased significantly 
during clodronate treatment reflecting reduced bone turnover.  
 
3. Tamoxifen treatment after adjuvant chemotherapy had opposite effects on 
BMD depending on menstrual status. Tamoxifen caused bone loss in patients 
who continued to menstruate after adjuvant chemotherapy. Contrarily, 
tamoxifen decreased bone loss in those women who developed chemotherapy-
induced amenorrhea. 
 
4. Changes in serum lipid levels during the chemotherapy correlated significantly 
with menstrual function. Only patients who developed signs of ovarian failure 
had marked elevations in serum total and LDL cholesterol. Tamoxifen 
treatment reversed the adverse effects of chemotherapy-induced ovarian 
failure on total and LDL cholesterol and even lowered serum levels below the 
baseline. 
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